Get documents about "Download the August 2012 Funding Newsletter - Sylvester
Document Sample
FUNDING NEWSLETTER
AUGUST 2012
NIH NOTICES AUGUST DEADLINES
Extramural Loan Repayment Program for
Pediatric Research (LRP-PR) (NOT-OD-12-125 ) Foundation and Other Sources
National Institutes of Health
"http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12- James & Esther King Biomedical Research
125.html" Program
Extramural Loan Repayment Program for Health Bridge Grants
Disparities Research (LRP-HDR) (NOT-OD-12-126) Deadline: August 31, 2012
National Institutes of Health "http://forms.floridabiomed.com/jek_call/King%20Bridge%20
Call%2012-13.pdf"
"http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-
126.html" About
The intent of the Bridge mechanism for the James & Esther
NIH FCOI Reporting Requirements and Demo - King Program is to provide interim support for promising
Webinar, August 14, 2012 - Registration Open tobacco-related investigator-initiated research projects that
(NOT-OD-12-122) have been highly rated by national panels of peer reviewers
National Institutes of Health in recent federal competitions but were not funded due to
budgetary constraints. Allowable federal competitions
"http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-
include those conducted by the National Institutes of Health,
122.html"
the Department of Defense Congressionally Directed
Extramural Loan Repayment Program for Clinical Medical Research Programs, the National Science
Foundation, the Agency for Healthcare Research and
Researchers (LRP-CR) (NOT-OD-12-123)
Quality, the Health Resources and Services Administration,
National Institutes of Health the Centers for Disease Control and Prevention, and the
"http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12- Food and Drug Administration.
123.html"
Period of Support Up to 1 year
Extramural Clinical Research Loan Repayment Funds/Direct Costs $200,000 (direct and indirect costs)
Program for Clinical Researchers from per year
Disadvantaged Backgrounds (LRP-IDB) (NOT-OD- Budgetary Notes 15% indirect costs are allowed
12-124) Program Contact Sarah Mesa
National Institutes of Health 400 SW Longview Boulevard, Suite
"http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12- 290
124.html" Lee's Summit, MO 64081
(816) 347-9449
programsupport@floridabiomed.com
Bankhead-Coley Cancer Research Program
Bridge Grants
Deadline: August 31, 2012
"http://forms.floridabiomed.com/bc_call/BC%20Bridge%20C
all%2012-13.pdf"
About
The intent of the Bridge mechanism for the Bankhead-Coley
Program is to provide interim support for promising cancer-
related investigator-initiated research projects that have
been highly rated by national panels of peer reviewers in
recent federal competitions but were not funded due to
budgetary constraints. Allowable federal competitions
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 1 of 45
include those conducted by the National Institutes of Health, Department of Defense
the Department of Defense Congressionally Directed
Prostate Cancer Research Program
Medical Research Programs, the National Science
Foundation, the Agency for Healthcare Research and Transformative Impact Award
Quality, the Health Resources and Services Administration, Preliminary Application Due: May 3, 2012
the Centers for Disease Control and Prevention, and the Application Due Date: August 23, 2012
Food and Drug Administration. All applicants must clearly "http://cdmrp.army.mil/funding/pa/12pcrptia_pa.pdf"
demonstrate how the proposed project is relevant to
cancer. Biomedical and biotechnological research projects About
must address the etiology, pathogenesis, prevention, The Prostate Cancer Research Program (PCRP)
diagnosis, treatment, and/or cure of cancer. Social Transformative Impact Award supports prostate cancer
scientific and behavioral proposals must address the research with near-term clinical relevance that will transform
development, implementation, and/or evaluation of existing and revolutionize the clinical management of prostate
or novel approaches to cancer prevention, diagnosis, or cancer, to include the wide spectrum of screening,
treatment. detection, diagnosis, prognosis, and/or treatment), and have
a major impact on the elimination of death and suffering
Period of Support Up to 1 year from prostate cancer. Although research that is deemed
Funds/Direct Costs $200,000 (direct and indirect costs) transformative must contend with potential risks, the
per year proposed project(s) must be supported by thorough review
Budgetary Notes 15% indirect costs are allowed of the literature, and sound rationale and well-designed
Program Contact Glenda Sapp research strategy. Applications must include substantive
400 SW Longview Boulevard, Suite preliminary data to support the rationale and feasibility of the
290 study.
Lee's Summit, MO 64081 Period of Support Up to 3 years
(816) 347-9449 Funds/Direct Costs $6M direct costs plus indirect costs
bcprogramsupport@floridabiomed.co for entire period of support
m Program Contact Congressionally Directed Medical
Research Programs
1077 Patchel Street
Children's Tumor Foundation Fort Detrick, MD 21702-5024
Drug Discovery Initiative Awards and Advanced help@cdmrp.org
Awards
Deadline: August 31, 2012
American Gastroenterological Association
"http://www.ctf.org/For-Scientists/drug-discovery-
initiative.html" AGA-R. Robert and Sally Funderburg Research
About
Award in Gastric Cancer
There is currently no effective drug treatment for Application Due Date: August 31, 2012
neurofibromatosis (NF). To help change that, the Drug "http://www.gastro.org/aga-foundation/grants/Criteria-
Discovery Initiative (DDI) funds and facilitates preclinical Funderburg_9-7-11.pdf"
screening of candidate treatments for NF. Advanced awards About
are available only to individuals who have previously The sponsor supports an established investigator working
received an in vivo DDI Award. on novel approaches in gastric cancer research, including
Period of Support Up to 1 year the fields of gastric mucosal cell biology; regeneration and
Funds/Direct Costs $25,000 for in vitro awards, $50,000 regulation of cell growth (not as they relate to peptic ulcer
for in vivo awards, advanced awards disease or repair); inflammation (including Helicobacter
up to $75,000 (all awards include pylori) as precancerous lesions; genetics of gastric
budget + fringe/indirect) carcinoma; oncogenes in gastric epithelial malignancies;
Budgetary Notes Up to 10% indirect costs are allowed epidemiology of gastric cancer; etiology of gastric epithelial
malignancies; or clinical research in the diagnosis or
Program Contact Min Wong treatment of gastric carcinoma.
95 Pine Street, 16th Floor
Period of Support Up to 2 years
New York, NY 10005
Funds/Direct Costs $50,000 per year
(212) 344-6633
Budgetary Notes Indirect costs are not allowed
mwong@ctf.org
Program Contact Research Awards Manager
4930 Del Ray Avenue
Bethesda, MD 20814
(301) 222-4012
awards@gastro.org
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 2 of 45
National Lung Cancer Partnership Department of Defense
Young Investigator Research Grant Prostate Cancer Research Program Laboratory-
Application Due Date: August 20, 2012 Clinical Transition Award
"http://www.nationallungcancerpartnership.org/images/uploa Preliminary Application Due: May 3, 2012
ds/files/Partnership_YIRG%20RFA_FINAL_2012.pdf" Application Due Date: August 23, 2012
About "http://cdmrp.army.mil/funding/pa/12pcrplcta_pa.pdf"
The purpose of this Grant Program is to drive research About
forward that will increase understanding of lung cancer, The Prostate Cancer Research Program Laboratory-Clinical
while ensuring that young investigators have the resources Transition Award (LCTA) supports product-driven preclinical
needed for them to succeed as lung cancer researchers. studies of promising lead agents or medical devices that
Basic, translational or clinical proposals are eligible for have the potential to revolutionize prostate cancer clinical
funding. Research that will lead to significant improvement care. This award is intended to fund Principal Investigators
in lung cancer prevention, detection, diagnosis, screening, (PIs) who lack support to conduct the preclinical studies
treatment, and symptom management is sought. The Young needed to advance lead agents or medical devices to
Investigator Research Grant is intended as seed money for human testing.
young investigators to carry out promising novel research in
any facet of non-small cell or small cell lung cancer. The Period of Support Up to 3 years
National Lung Cancer Partnership will not consider research Funds/Direct Costs $1.5M direct costs and indirect costs
related to mesothelioma, thymic or other thoracic over entire period of support
malignancies, or smoking prevention/cessation (if not Program Contact Congressionally Directed Medical
directly tied to treatment or care of lung cancer patients). Research Programs
Period of Support Up to 2 years 1077 Patchel Street
Funds/Direct Costs $50,000 direct costs per year Fort Detrick, MD 21702-5024
Budgetary Notes Up to 8% indirect costs (301) 682-5507
Program Contact Alice Yuroff, PhD help@cdmrp.org
1 Point Place, Suite 200
Madison, WI 53719 Department of Defense
(608) 233-7905
Lung Cancer Research Program Concept Award
Alice@NationalLungCancerPartnershi
p.org Preliminary Application Due: August 9, 2012
Application Due Date: August 23, 2012
"http://cdmrp.army.mil/funding/pa/12lcrpca_pa.pdf"
NEW
About
Bayer HealthCare The Lung Cancer Research Program (LCRP) Concept
Grants4Targets Award mechanism supports the exploration of a highly
Application Due Date: August 31, 2012 innovative new concept or untested theory that addresses
"http://www.grants4targets.com/scripts/pages/en/looking.php an important problem relevant to lung cancer. The Concept
" Award is not intended to support a logical progression of an
already established research project but, instead, allows
About Principal Investigators (PIs) the opportunity to pursue
The sponsor is interested in novel drug targets in the field of serendipitous observations. This award mechanism
oncology: focusing on anti-proliferative, survival signaling, supports high-risk studies that have the potential to reveal
transcription and chromatin modulation, cell cycle entirely new avenues for investigation. Applications must
regulation, tumor metabolism, hypoxia, immunotherapy and describe how the new idea will enhance the existing
antibody-drug conjugates. Support Grants further advance knowledge of lung cancer or create an entirely new avenue
research on targets that are at a very early stage of for investigation. Submissions from and partnerships with
discovery. Focus Grants are for more mature ideas, e.g. to investigators at Military Medical Treatment Facilities, Military
address specific aspects of a target as a first step towards labs, the Department of Veterans Affairs (VA) Medical
transferring it to the drug discovery process. Centers, and research laboratories and commercial
Not specified organizations are encouraged. Research completed through
Period of Support
a Concept Award may generate sufficient preliminary data
Funds/Direct Costs Support Grants (approx. U.S. $6000 to enable the PI to prepare an application for future
to $12,000); Focus Grants (approx. research.
U.S. $12,000 to $159,000)
Program Contact Dr. Heidrun Dorsch
United Kingdom
49(0)30-4681-5822
grants.for.targets@bayer.com
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 3 of 45
Period of Support Up to 1 year About
Funds/Direct Costs $100,000 direct costs plus indirect Ovarian Cancer Research Fund is requesting Letters of
costs for entire period of support Intent for the 2013 Ann Schreiber Research Training
Program Contact Congressionally Directed Medical Programs of Excellence grant. This grant provides funding
Research Programs for trainees who are working under the supervision of a
mentor who is a recognized leader in the field of ovarian
1077 Patchel Street
cancer research, or relevant area. Applicants should be
Fort Detrick, MD 21702-5024 involved in either laboratory, clinical, or epidemiology
(301) 682-5507 research. The research leader who will serve as the mentor
help@cdmrp.org should have significant independent cancer research
funding (NCI, DOD, etc.).
Period of Support Up to 2 years
Department of Defense
Funds/Direct Costs $75,000 total costs
Prostate Cancer Research Program Clinical Program Contact Sarah DeFeo
Exploration Award 14 Penn Plaza, Suite 1710
Preliminary Application Due: May 3, 2012 New York, NY 10122
Application Due Date: August 23, 2012 (212) 268-1002
"http://cdmrp.army.mil/funding/pa/12pcrpcea_pa.pdf" grants@ocrf.org
About
The intent of the Prostate Cancer Research Program
(PCRP) Clinical Exploration Award is to support early- NEW
phase, proof-of-principle clinical trials and correlative American Association for Cancer Research (AACR)
studies to investigate hypothesis-based, innovative Kure It Grant for Kidney Cancer Research
interventions and/or avenues of research that have the
potential to resolve current clinical barriers and result in a Application Due Date: August 21, 2012
profound impact on the management of prostate cancer. "http://www.aacr.org/Uploads/DocumentRepository/Grants/K
While therapeutic approaches proposed for testing through ureIt-AACR_Grants_PG.pdf"
the CEA must represent novel, hypothesis-based, “outside- About
the-box” approaches for treating prostate cancer, they may Applications are invited from researchers currently in the
include therapies already in clinical use, or undergoing field as well as from investigators with experience in other
clinical testing, for other diseases, provided that the areas of cancer research who have promising ideas or
proposed use for prostate cancer would lead to a major research approaches that can be applied to kidney cancer
advancement for treating the disease. It is anticipated that research. This grant will support an innovative translational
outcomes from studies funded by this award will provide research project designed to improve the survival and
scientific rationale for subsequent development of larger, quality of life of patients with kidney cancer and lead to
efficacy-based clinical trials of interventions that will individualized therapeutic options for treatment or the
transform prostate cancer clinical care. development of promising new cancer therapeutics for
Period of Support Up to 3 years kidney cancer. Emphasis will be placed on proposed
Funds/Direct Costs $450,000 direct costs plus indirect projects which will translate into clinical applications within a
costs for entire period of support few year period.
Program Contact Congressionally Directed Medical Period of Support Up to 2 years
Research Programs Funds/Direct Costs $125,000 total costs per year
1077 Patchel Street Budgetary Notes Up to 10% indirect costs are allowed
Fort Detrick, MD 21702-5024 Program Contact Ms. Allyson Browning
(301) 682-5507 615 Chestnut Street, 17th Floor
help@cdmrp.org Philadelphia,, PA 19106-4404
(215) 446-7269
grants@aacr.org
Ovarian Cancer Research Fund
Ann Schreiber Research Training Programs of
Excellence Department of Defense
Letter of Intent Due Date: May 29, 2012 Prostate Cancer Research Program Biomarker
Application Due Date: August 20, 2012 Development Award
"http://www.ocrf.org/images/pdfs/poe.loi.rfp.2013.doc" Preliminary Application Due: May 3, 2012
Application Due Date: August 23, 2012
"http://cdmrp.army.mil/funding/pa/12pcrpbda_pa.pdf"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 4 of 45
About Request for Applications (RFA)
The intent of the Biomarker Development Award is to
support the near-term translation of prostate cancer
Multiple Institutes, including the National Cancer
biomarkers to clinical practice. Specifically, this award will
support high-impact research aimed at qualifying or Institute
validating prostate cancer biomarkers for crucial decision- Leadership Group for a Clinical Research Network
making in prostate cancer management, including detection on Therapeutics for HIV/AIDS and HIV-associated
of aggressive disease, prognosis and progression, and Infections in Adults (UM1)
prediction and assessment of response to therapy.
Proposed projects should demonstrate a high potential for RFA-AI-12-004
commercialization and clinical use of the projects’ Letter of Intent Due Date: August 28, 2012
outcomes. As such, the inclusion of clinical trials is allowed. Application Due Date: September 28, 2012
It is the responsibility of the Principal Investigator (PI) to "http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-
clearly articulate the potential near-term impact of the study 004.html"
on current clinical practice for prostate cancer management.
Due to the expectation for near-term impact, studies toward About
discovery of new biomarkers or studies in model systems to The purpose of this Funding Opportunity Announcement
improve or refine biomarkers are not consistent with the (FOA) is to encourage applications for the Leadership
intent of this award mechanism. Group for a Clinical Research Network on Therapeutics for
HIV/AIDS and HIV-associated Infections in Adults. The
Period of Support Up to 3 years Leadership Group (LG) will have overall responsibility for
Funds/Direct Costs $2.25M direct costs plus indirect developing, implementing and adapting the network’s
costs for entire period of support clinical research agenda to address NIAID’s HIV/AIDS
Program Contact Congressionally Directed Medical scientific priorities. Applications for the LG must be
Research Programs comprised of three separate linked applications: a
1077 Patchel Street Leadership and Operations Center (LOC), a Laboratory
Fort Detrick, MD 21702-5024 Center (LC) and a Statistical and Data Management Center
(SDMC). NCI may help support studies of viruses
(301) 682-5507 responsible for causing HIV/AIDS-associated malignancies
help@cdmrp.org and strategies to prevent and detect the development of
malignancies in HIV-infected individuals. This FOA utilizes
the NIH Multi-Component Research Project Cooperative
Intramural Funding Opportunities Agreements (UM1) grant mechanism.
Period of Support Up to 7 years
NEW $35.93M total costs for FY14 to be
Funds/Direct Costs
Sylvester Comprehensive Cancer Center disbursed, as Core funding, among
Sylvester Investigator Initiated Trials (IIT) Grant the three awards constituting the
Program Leadership Group
Deadline: August 31, 2012 Program Contact Peter R. Jackson, PhD
6700-B Rockledge Drive, Room 3133
About
Bethesda, MD 20892-7616
A major goal of the Sylvester Comprehensive Cancer
(301) 496-8426
Center is to support the development of cancer focused
investigated initiated trials. These types of trials continue to pjackson@niaid.nih.gov
be a high priority regarding clinical research and historically
have been proven to be underfunded. In order to maintain
the continuity of our investigator initiated trials, funds will be Multiple Institutes, including the National Cancer
provided to sustain trials that are competitive for external Institute
funding. Only Cancer Center Faculty Members may apply. U.S.-China Program for Biomedical Collaborative
Trial must have received PRC approval to be considered. Research (R01)
Period of Support Up to 1 year RFA-AI-12-021
Funds/Direct Costs Up to $30,000 per year, only patient Letter of Intent Due Date: August 18, 2012
care costs and IRB fees are allowed
Application Due Date: September 18, 2012
Program Contact Giselle Arana
"http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-
1550 NW 10th Avenue, Fox 403 021.html"
Miami, FL 33136
(305) 243-6292
garana@med.miami.edu
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 5 of 45
About About
The purpose of the U.S.-China Program for Biomedical The purpose of the Lymphoma Research Foundation’s
Collaborative Research is to stimulate collaborative basic, (LRF’s) Clinical Investigator Career Development Award is
translational, and applied research between United States to fund training of physician investigators who will participate
(U.S.)-based researchers and Chinese researchers in the in developing new therapeutics and diagnostic tools for
areas of allergy, immunology, and infectious diseases lymphoma. Physician investigators who are at the level of
including HIV/AIDS and its co-morbidities and co-infections, advanced fellow or junior faculty member with no greater
cancer, mental health, Parkinson’s disease (PD), and than 5 years of experience beyond completion of their
stroke. Applications that propose to study cancer only and fellowship or post-doctoral training are eligible (five year limit
do not have an infectious agent and/or disease component may be non-sequential in case of interruptions for
will be considered nonresponsive and will not be reviewed. pregnancy or illness).The focus of the training is to prepare
This Funding Opportunity Announcement utilizes the NIH physician investigators to design and administer clinical
(R01) Research Project Grant mechanism. research studies in lymphoma and to take on the primary
responsibilities for clinical research, protocol writing,
Period of Support Up to 3 years Institutional Review Board (IRB) submission and publication.
Funds/Direct Costs $200,000 total costs per year The proposed research plan should develop the necessary
Program Contact Elizabeth Read-Connole knowledge and clinical research skills relevant to the
6130 Executive Boulevard, EPN 5016 investigator’s career goals. The Grant is designed to provide
Rockville, MD 20892 physician investigators with support to spend 35-50% of
their time implementing clinical research studies in
(301) 496-9740
lymphoma.
bconnole@mail.nih.gov
Period of Support Up to 3 years
Funds/Direct Costs $75,000 per year
Budgetary Notes Indirect costs are not allowed
Program Contact Research Department/CDA
SEPTEMBER/OCTOBER 115 Broadway, Suite 1301
New York, NY 10006
DEADLINES (212) 349-2910
researchgrants@lymphoma.org
Foundation and Other Sources
American Cancer Society
Alex's Lemonade Stand Research Scholar Grants
"A" Award Deadline: October 15, 2012
Application Due Date: September 17, 2012 "http://www.cancer.org/acs/groups/content/@researchadmini
"http://www.alexslemonade.org/files/grants_a_award.pdf" stration/documents/document/acspc-027414.pdf"
About About
This grant is designed for young scientists who want to Research Scholar Grants provide the resources for
jump-start their career in pediatric oncology research. The investigator-initiated research in a variety of cancer-relevant
ideal candidate has an original project that is not currently areas. Applicants must be independent, self-directed
being funded. Demonstration of outstanding mentorship and researchers within six years of their first academic
a future commitment to pediatric cancer investigation are appointment. The only eligibility exception is in the Priority
critical components of a successful application. Program in Cancer Control: research studies in
psychosocial, behavioral, health policy or health services
Period of Support Up to 3 years research studies that address cancer health disparities. In
Funds/Direct Costs $125,000 per year this case, investigators can be at any stage of their career.
Budgetary Notes Indirect costs are not allowed Period of Support Up to 4 years
Program Contact Kay Schaul Funds/Direct Costs $200,000 direct costs per year
333 E. Lancaster Avenue, #414 Budgetary Notes 20% indirect costs are allowed
Wynnewood, PA 19096 Program Contact Extramural Grants Department
(610) 649-3034 250 Williams Street, NW, 6th Floor
grants@alexslemonade.org Atlanta, GA 30303-1002
(404) 329-7558
Lymphoma Research Foundation grants@cancer.org
Clinical Investigator Career Development Award
Application Due Date: September 3, 2012
"http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E
&b=6330663"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 6 of 45
American Cancer Society Department of Defense
Mentored Research Scholar Grants in Applied and Peer Reviewed Cancer Research Program Career
Clinical Research Development Award
Deadline: October 15, 2012 Preliminary Application Due: June 19, 2012
"http://www.cancer.org/acs/groups/content/@researchadmini Application Due Date: September 12, 2012
stration/documents/document/acspc-027414.pdf" "http://cdmrp.army.mil/funding/pa/12prcrpcda_pa.pdf"
About About
The Mentored Research Scholar Grants in Applied and The Peer Reviewed Cancer Research Program (PRCRP)
Clinical Research provides support for mentored research Career Development Award mechanism supports the next
and training to full-time junior faculty, typically within the generation of cancer research. This award offers
initial four years of their first independent appointment. The opportunity for individuals in the early stages of their careers
goal is for these beginning investigators to become to obtain the funding, mentoring, and experience necessary
independent researchers as either clinician scientists or to advance an independent position at the forefront of
cancer control and prevention researchers. cancer research. The Career Development Award is
Period of Support Up to 5 years intended to support novel and innovative research projects
Funds/Direct Costs $135,000 direct costs per year with an emphasis on discovery. Preliminary data is not
required. The proposed research project should include a
Budgetary Notes 8% indirect costs are allowed
well-formulated, testable hypothesis based on strong
Program Contact Extramural Grants Department scientific rationale and study design.
250 Williams Street, NW, 6th Floor
Period of Support Up to 2 years
Atlanta, GA 30303-1002
Funds/Direct Costs $240,000 direct plus indirect costs
(404) 329-7558 over entire period of support
grants@cancer.org Program Contact Congressionally Directed Medical
Research Programs
Skin Cancer Foundation 1077 Patchel Street
Research Grant Awards Program Fort Detrick, MD 21702-5024
Application Due Date: October 5, 2012 (301) 682-5507
"http://www.skincancer.org/for-medical- help@cdmrp.org
professionals/research-grants/2013-research-grants"
About Department of Defense
The Skin Cancer Foundation is now accepting applications Lung Cancer Research Program Idea
for support of pilot research projects related to skin cancer. Development Award
The Foundation funds basic research and clinical studies Preliminary Application Due: May 30, 2012
which address improved methods of prevention, detection,
and treatment of skin cancer. The Foundation's Research Application Due Date: September 20, 2012
Grant Awards Program is intended for pilot projects, which, "http://cdmrp.army.mil/funding/pa/12lcrpida_pa.pdf"
if successful, can be developed to the point where they are About
eligible for larger grants from other sources. Research must The Idea Development Award is designed to promote new
be conducted by dermatology residents, fellows, and young ideas that are still in the early stages of development and
faculty (5-10 years post first academic appointment). have the potential to yield impactful data and new avenues
Preference is given to projects that address, at the basic of investigation. This mechanism supports conceptually
science and clinical level, improved methods of prevention, innovative, high-risk/high-reward research that could lead to
detection, and treatment of skin cancers. critical discoveries or major advancements that will
Period of Support Up to 1 year accelerate progress toward eradicating deaths from lung
Funds/Direct Costs $10,000, $15,000, or $25,000 direct cancer. The project’s impact to both lung cancer research
costs and to lung cancer patients should be articulated, even if
Budgetary Notes Indirect costs are not allowed clinical impact is not an immediate outcome. The PI must be
an independent investigator at or above the level of
Program Contact Skin Cancer Foundation Assistant Professor (or equivalent), and be within 10 years
149 Madison Avenue, Suite 901 of his/her first faculty appointment (or equivalent) by the
New York, NY 10016 time of the application submission deadline.
(212) 725-5176
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 7 of 45
Period of Support Up to 2 years Period of Support Varies per mechanism
Funds/Direct Costs $350,000 direct plus indirect costs Funds/Direct Costs Funds vary per mechanism - please
over entire period of support refer to website
Program Contact Congressionally Directed Medical Program Contact Extramural Grants Department
Research Programs 250 Williams Street NW, 6th Floor
1077 Patchel Street Atlanta, GA 30303
Fort Detrick, MD 21702-5024 (404) 329-7558
(301) 682-5507 grants@cancer.org
help@cdmrp.org
Conquer Cancer Foundation
American Cancer Society Young Investigator Award
Clinical Research Professor Award Application Due Date: September 27, 2012
Letter of Intent Due Date: August 1, 2012 "http://www.conquercancerfoundation.org/sites/conquercanc
Application Due Date: October 15, 2012 erfoundation.org/files/2013_yia_rfp_120524.pdf"
"http://www.cancer.org/acs/groups/content/@researchadmini About
stration/documents/document/acspc-023670.pdf" The Young Investigator Award (YIA) provides funding to
About promising investigators to encourage and promote quality
The American Cancer Society offers a limited number of research in clinical oncology. The purpose of this award is to
grants to provide unique research opportunities to foster fund physicians during the transition from a fellowship
maximal productivity in clinical and applied cancer research. program to a faculty appointment. The applicant must be a
These grants provide flexible funding for established physician (MD, DO, or international equivalent) who is
investigators in mid-career who have made seminal currently within the last two years of his/her final
contributions in areas of cancer control that have changed subspecialty training at an academic medical institution at
the direction of clinical, psychosocial, behavioral, health the time of grant submission. Applicants should be planning
policy or epidemiologic cancer research. Applicants will an investigative career in clinical oncology.
have attained the rank of full professor or equivalent and Period of Support Up to 1 year
must not have held the rank of full professor or the Funds/Direct Costs $50,000 per year
equivalent for more than 15 years.
Budgetary Notes Up to $2,500 indirect costs (or 5% of
Period of Support Up to 5 years the total award amount)
Funds/Direct Costs $80,000 direct costs per year Program Contact Conquer Cancer Foundation
Program Contact Extramural Grants Department 2318 Mill Road, Suite 800
250 Williams Street, NW, 6th Floor Alexandria, VA 22314
Atlanta, GA 30303-1002 grants@conquercancerfoundation.org
(404) 329-7558
grants@cancer.org Lymphoma Research Foundation
Postdoctoral Fellowships
NEW
Application Due Date: September 3, 2012
American Cancer Society "http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E
Priority Program in Cancer Health Disparities &b=6330663"
Research About
Application Due Date: October 15, 2012 The purpose of the Lymphoma Research Foundation
"http://www.cancer.org/acs/groups/content/@researchadmini Postdoctoral Fellowship is to support research, which may
stration/documents/document/acspc-025768.pdf" be laboratory or clinic based, with the results and
conclusions that must be clearly relevant to the treatment,
About
diagnosis or prevention of Hodgkin and/or non-Hodgkin
The American Cancer Society is committed to reducing
lymphoma. Areas of research may include, but are not
cancer health disparities and has set strategic priorities for
limited to, etiology, immunology, genetics, therapies, and
eliminating such disparities through research, education,
transplantation.
advocacy, and service. The Society has set as a nationwide
objective the goal of eliminating disparities in cancer
burdens by 2015. Applications will be accepted using one of
four mechanisms: Postdoctoral Fellowship, Mentored
Research Scholar Grant, Research Scholar Grant, or
Clinical Research Professor.
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 8 of 45
Period of Support Up to 2 years Period of Support Up to 3 years
Funds/Direct Costs Salary support only: $45,000 for the Funds/Direct Costs $150,000 direct costs per year
first year, $50,000 for the second Budgetary Notes Indirect costs are not allowed
year; and $5,000 per year for the
Program Contact Damon Runyon Cancer Research
research project
Foundation
Budgetary Notes Indirect costs are not allowed 55 Broadway, Suite 302
Program Contact Research Department/FEL New York, NY 10006
115 Broadway, Suite 1301 (212) 455-0520
New York, NY 10006 awards@damonrunyon.org
(212) 349-2910
researchgrants@lymphoma.org Department of Defense
Lung Cancer Research Program Translational
NEW
Research Partnership Award
American Cancer Society
Preliminary Application Due: May 30, 2012
Doctoral Training Grants in Clinical Oncology Application Due Date: September 20, 2012
Social Work "http://cdmrp.army.mil/funding/pa/12lcrptrpa_pa.pdf"
Application Due Date: October 15, 2012
About
"http://www.cancer.org/acs/groups/content/@researchadmini
The key initiative of the Translational Research Partnership
stration/documents/document/acspc-025768.pdf"
Award is to encourage partnerships between clinicians and
About laboratory scientists that will accelerate the movement of
The sponsor annually awards Doctoral Training Grants in promising ideas in lung cancer into clinical applications. This
Oncology Social Work to doctoral students to conduct award supports the development of translational research
research related to the psychosocial needs of persons with collaborations between two independent, faculty level (or
cancer and their families. equivalent) investigators to address a central problem or
Period of Support Up to 4 years question in lung cancer in a manner that would be less
readily achievable through separate efforts. One partner in
Funds/Direct Costs $20,000 direct costs per year the collaboration must be a laboratory scientist and the
Budgetary Notes Indirect costs are not allowed other must be a clinician, and it should be clear that both
Program Contact Danielle Alsander have had equal intellectual input into the design of the
250 Williams Street, 6th Floor research project. Optional Nested Clinical Fellow or
Atlanta, GA 30303-1002 Resident Traineeship: The clinical fellow or resident trainee
must be enrolled in an accredited clinical fellowship or
(404) 329-5734
residency program by the time of the application submission
danielle.alsander@cancer.org deadline. The trainee must be able to devote a minimum of
40% level of effort for the 1-year period of performance of
Damon Runyon Cancer Research Foundation the traineeship.
Damon Runyon-Rachleff Innovation Award Period of Support Up to 3 years
Preliminary Application Due: June 1, 2012 Funds/Direct Costs $900,000 total direct costs plus
Application Due Date: September 4, 2012 indirect costs for entire period of
"http://www.damonrunyon.org/for_scientists/more/innovation support; additional $75,000 (direct
_award_overview" and indirect costs) may be requested
for Optional Nested Clinical Fellow or
About Resident
The award is specifically designed to provide funding for Traineeship for 1 year
extraordinary early career researchers who have an Program Contact Congressionally Directed Medical
innovative new idea but lack sufficient preliminary data to Research Programs
obtain traditional funding. It is not designed to fund 1077 Patchel Street
incremental advances. The research supported by the
Fort Detrick, MD 21702-5024
award must be novel, exceptionally creative and, if
successful, have the strong potential for high impact in the (301) 682-5507
cancer field. Applicants must belong to one of the following help@cdmrp.org
categories: Tenure-track Assistant Professors within the first
three years of obtaining their initial Assistant Professor American Cancer Society
position; Clinical Instructors and Senior Clinical Fellows (in
their final year of their sub-specialty training); Distinguished Cancer Control Career Development Awards for
Fellows with an exceptional record of research Primary Care Physicians
accomplishment. Application Due Date: October 15, 2012
"http://www.cancer.org/acs/groups/content/@researchadmini
stration/documents/document/acspc-027414.pdf"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 9 of 45
About About
Cancer Control Career Development Awards for Primary The Searle Scholars Program supports the independent
Care Physicians are intended to support primary care research of outstanding individuals who are in the first or
physicians in supervised programs intended to develop second year of their first appointment at the assistant
clinical and teaching expertise and the capacity to perform professor level, and whose current appointment is a tenure-
independent research or educational innovation in cancer track position. Applicants will be expected to be pursuing
control. independent research careers in biochemistry, cell biology,
Period of Support Up to 3 years genetics, immunology, neuroscience, pharmacology, and
related areas in chemistry, medicine, and the biological
Funds/Direct Costs $100,000 per year sciences.
Budgetary Notes A maximum of $10,000 per year for the
mentor(s) may be included in the budget Period of Support Up to 3 years
Program Contact Extramural Grants Department Funds/Direct Costs $100,000 per year
250 Williams Street, NW, 6th Floor Budgetary Notes Indirect costs are not allowed
Atlanta, GA 30303-1002 Internal Contact Karen Del Rio
(404) 329-7558 (305) 243-5370
grants@cancer.org kdelrio@miami.edu
Program Contact Jennifer Nesler
Department of Defense 303 W. Madison Street, Suite 1800
Chicago, IL 60606
Peer Reviewed Cancer Research Program
(312) 803-6200
Visionary Postdoctoral Fellowship Award
jennifer.nesler@kinshiptrustco.com
Preliminary Application Due: June 19, 2012
Application Due Date: September 12, 2012
NEW
"http://cdmrp.army.mil/funding/pa/12prcrpvpfa_pa.pdf"
American Cancer Society
About
Pilot and Exploratory Projects in Palliative Care of
The Visionary Postdoctoral Fellowship Award is intended to
support exceptionally talented, recent medical or other Cancer Patients and Their Families
doctoral graduates in their pursuit of cancer research during Application Due Date: October 15, 2012
a postdoctoral fellowship with a focus on cutting-edge, "http://www.cancer.org/acs/groups/content/@researchadmini
innovative, high-risk/high-impact basic science or stration/documents/document/acspc-025768.pdf"
translational research that will have either short-term or long-
About
term clinical impact. Translational research may include
The sponsor supports investigators performing pilot and
preclinical studies in animal models and/or human tissues
exploratory research studies that test interventions, develop
that have a clear potential for translation into clinical
research methodologies, and explore novel areas of
applications. Correlative studies of existing clinical trials,
research in palliative care of cancer patients and their
and/or projects that develop clinical endpoints for clinical
families.
trials, may also be proposed.
Period of Support Up to 3 years Period of Support Up to 2 years
Funds/Direct Costs $240,000 direct and indirect costs for Funds/Direct Costs $60,000 direct costs per year
the entire period of support Budgetary Notes 20% indirect costs are allowed
Program Contact Congressionally Directed Medical Program Contact Dr. Ronit Elk
Research Programs 250 Williams Street NW, 6th Floor
1077 Patchel Street Atlanta, GA 30303-1002
Fort Detrick, MD 21702-5024 (404) 329-7558
(301) 682-5507 ronit.elk@cancer.org
help@cdmrp.org
NEW
Searle Scholars Program Leukemia and Lymphoma Society
2013 Searle Scholars Program Career Development Program
Limited Nominations: 1 Letter of Intent Due Date: September 15, 2012
University of Miami Internal Application Due Date: October 1, 2012
Review Deadline: July 27, 2012 "http://www.lls.org/content/nationalcontent/pdf/researchers/2
Application Due Date: September 28, 2012 012CDguidelines"
"http://www.searlescholars.net"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 10 of 45
About About
The Leukemia & Lymphoma Society's (LLS's) Career The Career Development Award (CDA) is a research grant
Development Program (CDP) provides awards to support that provides funding to clinical investigators who have
blood cancer researchers in the early phase of their careers. received their initial faculty appointment to establish an
These individuals will continue to provide a foundation for independent clinical cancer research program. The cancer
the understanding, diagnosis, and development of treatment research must have a patient-oriented focus, including a
and prevention options that will ultimately lead to cures for clinical research study and/or translational research
blood cancer patients. Some examples of potentially involving human subjects. Proposals with a predominant
relevant research areas include but are not limited to: focus on in vitro or animal studies (even if clinically relevant)
experimental therapeutics, cell growth regulation, cell cycle are not allowed. The applicant must be a physician (MD,
regulation, DNA damage and repair, experimental DO, or international equivalent) who is within the 1st to 3rd
carcinogenesis, basic or applied immunology, innovations in year of a full-time, primary faculty appointment in a clinical
prevention, diagnosis or management, and study of department at the time of grant submission. Grant
infectious diseases of high frequency in immunodeficient applications from candidates with existing career
patients. Funded projects frequently involve molecular development awards (such as K23, K08, or any other type
genetics, transgenetics, genomics, proteomics, and/or other of career development award) will not be considered.
cutting edge molecular and cellular technologies. Period of Support Up to 3 years
Period of Support Up to 5 years Funds/Direct Costs $66,666 total costs per year
Funds/Direct Costs Funds vary per award - please refer Budgetary Notes Up to $4,200 per year (or 6.3% of the
to website yearly total award amount) indirect costs
Budgetary Notes Up to 5% indirect costs are allowed are allowed
Program Contact Director of Research Administration Program Contact Conquer Cancer Foundation
1311 Mamaroneck Avenue, Suite 310 2318 Mill Road, Suite 800
White Plains, NY 10605 Alexandria, VA 22314
(914) 821-8301 grants@conquercancerfoundation.org
researchprograms@lls.org
Cancer Research Institute
American Cancer Society Irvington Institute Fellowship Program
Postdoctoral Fellowships Application Due Date: October 1, 2012
Deadline: October 15, 2012 "http://www.cancerresearch.org/programs/research/fellowshi
"http://www.cancer.org/acs/groups/content/@researchadmini p/apply.html#Program_Description"
stration/documents/document/acspc-027414.pdf" About
About The Irvington Institute Fellowship Program was established
The sponsor provides support for the training of researchers to answer the need for more researchers in the field of
who have received a doctoral degree to provide initial cancer immunology. It supports qualified young scientists at
funding leading to an independent career in cancer research leading universities and research centers around the world
(including basic, preclinical, clinical, cancer control, who wish to receive training in cancer immunology.
psychosocial, behavioral, epidemiology, health services and Applicants must have a doctoral degree by the date of
health policy research). award activation and must conduct their proposed research
under a sponsor who holds a formal appointment at the host
Period of Support Up to 3 years
institution. Applicants with 5 or more years of relevant
Funds/Direct Costs Progressive stipends of $44,000, postdoctoral experience are not eligible, with the exception
$46,000, and $48,000 per year, plus of M.D. applicants, who should not include years of
a $4,000 per year fellowship residency in this calculation.
allowance
Period of Support Up to 3 years
Program Contact Extramural Grants Department
Funds/Direct Costs 1st Year: $50,000; 2nd Year:
250 Williams Street, NW, 6th Floor
$53,000; 3rd Year: $57,000.
Atlanta, GA 30303-1002
Budgetary Notes Indirect costs are not allowed
(404) 329-7558
Program Contact Cancer Research Institute
grants@cancer.org
One Exchange Plaza, 55 Broadway,
Suite 1802
Conquer Cancer Foundation New York, NY 10006
Career Development Award (212) 688-7515
Application Due Date: September 27, 2012 grants@cancerresearch.org
"http://www.conquercancerfoundation.org/sites/conquercanc
erfoundation.org/files/2013_cda_rfp_120524.pdf" Program Announcements (PA)
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 11 of 45
Multiple Institutes, including the National Cancer Multiple Institutes, including the National Cancer
Institute Institute
Structural Biology of Membrane Proteins (R01) Mechanisms, Models, Measurement, &
PA-10-228 Management in Pain Research (R01)
Deadline: October 5, 2012 PA-10-006
"http://grants.nih.gov/grants/guide/pa-files/PA-10-228.html" Deadline: October 5, 2012
About "http://grants.nih.gov/grants/guide/pa-files/PA-10-006.html"
This Funding Opportunity Announcement (FOA)
About
encourages grant applications from
The purpose of this Funding Opportunity Announcement
institutions/organizations that propose to develop research
(FOA), “Mechanisms, Models, Measurement, &
and methods to enhance the rate of membrane protein
Management in Pain Research” issued by the National
structure determination and to determine specific
Institute of Nursing Research (NINR), in conjunction with
membrane protein structures. Innovative methods for
members of the NIH Pain Consortium as listed above, is to
expression, oligomerization, solubilization, stabilization,
inform the scientific community of the pain research
purification, characterization, crystallization, isotopic
interests of the various Institutes and Centers (ICs) at the
labeling, and structure determination of unique and
National Institutes of Health (NIH) and to stimulate and
biologically significant membrane proteins by x-ray
foster a wide range of basic, clinical, and translational
diffraction, nuclear magnetic resonance (NMR), electron
studies on pain as they relate to the missions of these ICs.
microscopy, mass spectrometry, and other biophysical
New advances are needed in every area of pain research,
techniques are encouraged. Projects that will lead in the
from the micro perspective of molecular sciences to the
near term to determining the structures of biologically
macro perspective of behavioral and social sciences.
important membrane proteins are also encouraged. This
Although great strides have been made in some areas, such
FOA utilizes the NIH Research Project (R01) grant
as the identification of neural pathways of pain, the
mechanism.
experience of pain and the challenge of treatment have
Period of Support Up to 5 years remained uniquely individual and unsolved. Furthermore,
Program Contact Leo Buscher our understanding of how and why individuals transition to a
6120 Executive Boulevard, Room 234 chronic pain state after an acute insult is limited. Research
Bethesda, MD 20892-7148 to address these issues conducted by interdisciplinary and
multidisciplinary research teams is strongly encouraged, as
(301) 496-7753
is research from underrepresented, minority, disabled, or
buscherel@gab.nci.nih.gov women investigators. This FOA will utilize the NIH Research
Project Grant (R01) grant mechanism.
National Cancer Institute Period of Support Up to 5 years
Image-Guided Drug Delivery in Cancer (R01) Program Contact Dr. Susan Marden, PhD
PA-09-253 6701 Democracy Blvd., Suite 710
Deadline: October 5, 2012 Bethesda, MD 20892-4870
"http://grants.nih.gov/grants/guide/pa-files/PA-09-253.html" (301) 496-9623
About mardens@mail.nih.gov
This Funding Opportunity Announcement (FOA)
encourages innovative translational research in the National Cancer Institute
development of quantitative in vivo imaging characterization Epigenetic Approaches in Cancer Epidemiology
of image-guided drug delivery (IGDD) in cancer, including
(R01)
characterizations of the target, delivery validation, and
therapy response. This FOA will support research in PA-10-031
development of integrated imaging-based platforms for Deadline: October 5, 2012
multifunctional and multiplexed drug delivery systems in "http://grants1.nih.gov/grants/guide/pa-files/PA-10-031.html"
cancer. Validation studies in non-human primates or large
animal models and first in human studies directed towards About
translation of IGDD technology into the clinic will be This Funding Opportunity Announcement (FOA)
considered appropriate for this FOA. This FOA will utilize encourages research applications that propose to evaluate
the Research Project Grant (R01) grant mechanism. profiles of methylation, histone modifications and micro RNA
(miRNA) and their association with risk of developing cancer
Period of Support Up to 5 years in different populations. The overarching goal of this FOA is
Funds/Direct Costs $500,000 per year to provide support for population based studies to define the
Program Contact Pushpa Tandon, PhD role of epigenetic markers (methylation, histone and micro
6130 Executive Boulevard, EPN 6048 RNA profiles) changes to understand cancer etiology. This
Bethesda, MD 20892-7412 FOA will utilize the research project (R01) grant mechanism.
(301) 451-2291
tandonp@mail.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 12 of 45
Period of Support Up to 5 years evaluate small molecules for use in elucidating molecular,
Program Contact Mukesh Verma, PhD cellular, or in vivo mechanisms or processes of probable or
known importance to cancer biology, and for use in
6130 Executive Boulevard, EPN
developing strategies for cancer prevention, diagnosis,
Room 5100
treatment or clinical monitoring of treatment. Assays
Bethesda, MD 20892-7234 proposed may be biochemical, cellular or model organism-
(301) 594-7344 based, and may be useful for discovering small molecule
vermam@mail.nih.gov probes, preventive or therapeutic drug leads, or imaging
agent leads. Applicants may find the NCI Developmental
Multiple Institutes, including the National Cancer Therapeutics Program (http://dtp.nci.nih.gov) resources to
be helpful. Collaborations between laboratories with screen
Institute development capabilities and laboratories with small
School Nutrition and Physical Activity Policies, molecule synthesis capabilities are encouraged. This FOA
Obesogenic Behaviors and Weight Outcomes will utilize the NIH Research Project (R01) grant mechanism.
(R01) Period of Support Up to 3 years
PA-10-052 Program Contact Ronald Margolis, PhD
Deadline: October 5, 2012 6707 Democracy Blvd., Room 693
"http://grants.nih.gov/grants/guide/pa-files/PA-10-052.html" Bethesda, MD 20892-5460
About 301-594-8819
This Funding Opportunity Announcement (FOA) margolisr@mail.nih.gov
encourages applications that propose to: (1) foster
multidisciplinary research that will evaluate how policies National Cancer Institute
(federal, state and school district levels) can influence
school physical activity and nutrition environments, youths’ Identifying Non-coding RNA Targets for Early
obesogenic behaviors (e.g., nutrition and physical activity Detection of Cancer (R01)
behaviors), and weight outcomes; (2) understand how PA-12-213
schools are implementing these policies and examine multi- Deadline: October 5, 2012
level influences on adoption and implementation at various
"http://grants1.nih.gov/grants/guide/pa-files/PA-12-213.html"
levels (e.g., federal, state, school district, and school); and
(3) understand the synergistic or counteractive effect of About
school nutrition and physical activity polices on the home This Funding Opportunity Announcement (FOA)
and community environment and body weight. encourages research projects on non-coding RNAs
Period of Support Up to 5 years (ncRNAs) and their targets in preneoplastic lesions and
early stage cancers. This FOA also encourages research
Program Contact Tanya Agurs-Collins, PhD, RD projects to assess the usefulness of stable microRNAs
6130 Executive Blvd., Room 4084 (miRNAs) and ncRNAs to predict progression to cancer and
Bethesda, MD 20892-7324 as biomarkers for early cancer detection and screening.
(301) 594-6637 Building on both basic and biomarker research on
collinsta@mail.nih.gov microRNAs (miRNA), this FOA will further promote research
on all classes of ncRNAs and support the translation of
stable miRNAs into cancer screening or diagnostic tests.
Multiple Institutes, including the National Cancer This FOA utilizes the NIH Research Project (R01) grant
Institute mechanism.
Development of Assays for High-Throughput Period of Support Up to 5 years
screening for use in Probe and Pre-therapeutic Program Contact Wendy Wang, PhD, MSc
Discovery (R01) 6130 Executive Boulevard, Room 3138
PA-10-213 Bethesda, MD 20852-7362
Deadline: October 5, 2012 (301) 594-7607
"http://grants1.nih.gov/grants/guide/pa-files/PA-10-213.html" wangw@mail.nih.gov
About
This Funding Opportunity Announcement (FOA) Multiple Institutes, including the National Cancer
encourages applications from institutions/organizations that Institute
propose the development of assays for high throughput Health Promotion Among Racial and Ethnic
screening (HTS) relevant to processes and diseases
specific to its mission with the intent of using them to screen Minority Males (R01)
for small molecule compounds that show desired properties PA-10-236
as probes for use in advancing knowledge about the Deadline: October 5, 2012
relevant target, identifying new targets, or serving as pre- "http://grants.nih.gov/grants/guide/pa-files/PA-10-236.html"
therapeutic leads. Assays pertinent to the mission of NCI
should be justified in the application as relevant to cancer.
The NCI is interested in development of assays to identify or
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 13 of 45
About Multiple Institutes, including the National Cancer
This Funding Opportunity Announcement (FOA) Institute
encourages applications from applicants that propose to
stimulate and expand research in the health of minority
Nutrition and Alcohol-Related Health Outcomes
men. Specifically, this initiative is intended to: 1) enhance (R01)
our understanding of the numerous factors (e.g., PA-10-239
sociodemographic, community, societal, personal) Deadline: October 5, 2012
influencing the health promoting behaviors of racial and "http://grants.nih.gov/grants/guide/pa-files/PA-10-239.html"
ethnic minority males and their subpopulations across the
life cycle, and 2) encourage applications focusing on the About
development and testing of culturally and linguistically This Funding Opportunity Announcement (FOA)
appropriate health-promoting interventions designed to encourages applications from institutions/organizations that
reduce health disparities among racially and ethnically propose to examine associations between nutrition and
diverse males and their subpopulations age 21 and older. alcohol-related health outcomes in humans and animal
This FOA utilizes the NIH Research Project (R01) grant models. The goal of this program announcement is to
mechanism. stimulate a broad range of research on the role of nutrition
in the development, prevention, and treatment of a variety of
Period of Support Up to 5 years
alcohol-related health outcomes including alcohol
Program Contact Carol A. Perry dependence and psychiatric co-morbidities, chronic and
6120 Executive Boulevard, Suite 243 acute diseases, and organ function and damage. Study
Bethesda, MD 20892-4870 designs may include biomedical research, epidemiologic
(301) 493-7205 approaches, and intervention studies. This FOA will utilize
perryc@mail.nih.gov the NIH Research Project (R01) grant mechanism.
Period of Support Up to 5 years
Multiple Institutes, including the National Cancer Program Contact Barbara Liesenfeld
Institute 6120 Executive Blvd., Room 243
Bioengineering Research Partnerships (BRP) (R01) Bethesda, MD 20892-7150
PAR-10-234 (301) 496-3265
liesenfb@mail.nih.gov
Deadline: October 5, 2012
"http://grants.nih.gov/grants/guide/pa-files/PAR-10-234.html"
Multiple Institutes, including the National Cancer
About Institute
Participating Institutes and Centers (ICs) of the National
Institutes of Health (NIH) invite applications for R01 awards Continued Development and Maintenance of
to support Bioengineering Research Partnerships (BRPs) Software (R01)
for basic, applied, and translational multi-disciplinary PAR-11-028
research that addresses important biological, clinical or Deadline: October 5, 2012
biomedical research problems. In the context of this
"http://grants.nih.gov/grants/guide/pa-files/PAR-11-028.html"
program, a partnership is a multi-disciplinary research team,
that applies an integrative, systems approach to develop About
knowledge and/or methods to prevent, detect, diagnose, or Biomedical research laboratories increasingly undertake a
treat disease or to understand health and behavior. The software development project to solve a problem of interest
partnership must operate according to a clear leadership specifically related to that laboratory. These software
plan and include appropriate bioengineering or allied packages sometimes become useful to a much broader
quantitative sciences in combination with biomedical and/or community of users that can include translational and
clinical components. It is expected that a BRP will have a clinical researchers. The goal of this program
well-defined goal or deliverable that will be achieved in a 5- announcement is to support the continued development,
10 year timeframe based on objective milestones specified maintenance, testing and evaluation of existing software.
in the initial application. The proposed work should apply best practices and proven
Period of Support Not specified methods for software design, construction, and
implementation to extend the applicability of existing
Funds/Direct Costs Up to $2M per year
biomedical informatics/computational biology software to a
Program Contact Sean Hine broader biomedical research community. This Funding
6120 Executive Blvd., Suite 243 Opportunity Announcement (FOA) will utilize the NIH
Rockville, MD 20852 Research Project (R01) grant mechanism.
301-846-1005 Period of Support Not specified
seanhine@nih.gov Program Contact Jerry Li, PhD
6130 Executive Blvd.
Rockville, MD 20892
(301) 435-5226
jiayinli@mail.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 14 of 45
applicable to disease control and prevention especially as
National Cancer Institute related to cancer and cancer patients. This FOA utilizes the
Quantitative Imaging for Evaluation of Responses R01 Research Project Grant mechanism.
to Cancer Therapies (U01) Period of Support Up to 5 years
PAR-11-150 Funds/Direct Costs Application budgets are not limited,
Deadline: October 5, 2012 but need to reflect actual needs of
"http://grants1.nih.gov/grants/guide/pa-files/PAR-11- the proposed project.
150.html" Program Contact Li Zhu, PhD
(301) 594-6546
About
This Funding Opportunity Announcement (FOA) is designed li.zhu@nih.gov
to promote research on quantitative imaging of tumor
response to cancer therapies in clinical trial settings, with National Cancer Institute
the overall goal of facilitating clinical decision making. Biomarkers for Early Detection of Hematopoietic
Proposed projects should include the appropriate
Malignancies (R01)
development and adaptation/implementation of quantitative
imaging methods, protocols and software solutions/tools PA-12-221
(using existing commercial imaging platforms and Deadline: October 5, 2012
instrumentation), and their application in current and "http://grants.nih.gov/grants/guide/pa-files/PA-12-221.html"
planned Phase 1-2 clinical therapy trials. No support for the
clinical trials, as such, will be provided under this FOA. The About
proposed projects must focus on imaging-derived This Funding Opportunity Announcement (FOA)
quantitative measurements of responses to drugs and/or encourages research projects for the development and
radiation therapy, and/or image-guided interventions. It is validation of biomarkers for: a) early detection, prediction of
anticipated that these research goals will require progression, and recurrence of hematopoietic malignancies,
multidisciplinary efforts. Therefore, this FOA encourages especially in high-risk individuals; and, b) for risk
applications from multi-disciplinary teams to include assessment of primary and secondary hematopoietic
oncologists as well as clinical and basic imaging scientists. malignancies. This FOA also encourages the development
The involvement of industrial partners in the development of and improvement of specific technologies and methods for
the quantitative imaging methods is not required, but is quantitative detection of novel biomarkers associated with
strongly encouraged. Awardees will form a Quantitative hematopoietic malignancies. This FOA utilizes the NIH
Imaging Network (QIN) to share ideas and approaches to Research Project (R01) award mechanism.
validate and standardize imaging data and related imaging Period of Support Up to 5 years
metadata for quantitative measurements of responses to Program Contact Lynn Sorbara, PhD
cancer therapies. 6130 Executive Boulevard, Room 3137
Period of Support Up to 5 years Bethesda, MD 20892-7362
Funds/Direct Costs $500,000 per year (301) 435-0584
Program Contact Robert J. Nordstrom, PhD lynns@mail.nih.gov
6130 Executive Blvd., Room 6071
Bethesda, MD 20892-7412 Multiple Institutes, including the National Cancer
(301) 496-3428 Institute
nordstrr@mail.nih.gov Collaborations with National Centers for
Biomedical Computing (R01)
Multiple Institutes, including the National Cancer PAR-12-001
Institute
Deadline: October 5, 2012
Spatial Uncertainty: Data, Modeling, and "http://grants.nih.gov/grants/guide/pa-files/PAR-12-001.html"
Communication (R01)
About
PA-11-238 This Funding Opportunity Announcement (FOA) is for
Deadline: October 5, 2012 projects from individual investigators or small groups to
"http://grants.nih.gov/grants/guide/pa-files/PA-11-238.html" collaborate with the NIH Common Fund for Medical
About Research National Centers for Biomedical Computing
(NCBCs). For a description of the NCBCs see
The purpose of this Funding Opportunity Announcement
http://www.ncbcs.org/. The intention of the collaborating
(FOA) is to support innovative research that identifies
projects is to engage researchers across the nation in
sources of spatial uncertainty (i.e., inaccuracy or instability
building an excellent biomedical computing environment,
of spatial or geographic information) in public health data,
using the computational tools and biological and behavioral
incorporates the inaccuracy or instability into statistical
application drivers of the funded NCBCs as foundation
methods, and develops novel tools to visualize the nature
stones. This FOA utilizes the NIH R01 Research Project
and consequences of spatial uncertainty. The National
Grant mechanism.
Cancer Institute (NCI) is interested in general methodology
of spatial statistical models and visualization tools that are
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 15 of 45
Period of Support Up to 5 years multiple comorbid conditions (e.g., hypertension and
Program Contact Jennifer Couch, PhD HIV/AIDS). Studies should use the most rigorous design
and methodology possible given the populations and
(301) 435-5226
settings in which the study is taking place. Primary
couchj@mail.nih.gov outcomes of the research should include: a patient self-
report of medication adherence, and at least one other non-
National Cancer Institute self-report measure of medication adherence (e.g.,
Development, Application, and Evaluation of pharmacy refill records, electronic monitoring, etc.). In
addition, applications should include a health outcome or
Prediction Models for Cancer Risk and Prognosis biomarker (e.g., blood pressure, viral load in HIV patients,
(R01) cholesterol levels, HbA1c) that is expected to be affected by
PA-10-025 changes in the targeted adherence behavior. Researchers
Deadline: October 5, 2012 should address the capacity of the tested approach for wide
"http://grants1.nih.gov/grants/guide/pa-files/PA-10-025.html" dissemination, the sustainability of the approach once the
research is concluded, and are encouraged to include
About measurement and costs of the intervention characteristics
The purpose of this Funding Opportunity Announcement and contextual factors that affect implementation and
(FOA) is to encourage clinicians, epidemiologists, adoption. This FOA utilizes the NIH R01 Research Project
geneticists, statisticians, and translational researchers Grant mechanism.
working in the field of cancer control and prevention to
Period of Support Not specified
improve existing models for cancer risk and prognosis by
developing innovative research projects that use existing Funds/Direct Costs Application budgets are not limited,
data; develop new models for cancer risk and prognosis; but need to reflect actual needs of
and validate new models and evaluate their utility in the proposed project
research and clinic settings. Applications that are focused Program Contact Wendy Nelson, PhD, MPH
on the identification and characterization of (301) 435-4590
prognostic/diagnostic markers are NOT appropriate for this nelsonw@mail.nih.gov
FOA. This FOA is designed to provide a mechanism of
support for investigators to address two major challenges in
model development, which are: integrating diverse types of Multiple Institutes, including the National Cancer
data (e.g., clinical, demographic, pathologic, environmental, Institute
epidemiologic, outcomes, and genetic data from varied data Systems Science and Health in the Behavioral and
marts or warehouses); and ensuring adequate validation Social Sciences (R01)
(i.e., using multiple separate populations to define
sensitivity, specificity, and positive and negative predictive
PAR-11-314
values). This FOA will utilize the R01 grant mechanism. Deadline: October 5, 2012
Period of Support Up to 5 years "http://grants.nih.gov/grants/guide/pa-files/PAR-11-314.html"
Program Contact Andrew Freedman, PhD About
6130 Executive Blvd, EPN Room 4005 This Funding Opportunity Announcement (FOA)
encourages applications that propose to develop basic and
Bethesda, MD 20892
applied projects utilizing systems science methodologies
(301) 435-6819 relevant to human behavioral and social sciences and
freedmaa@mail.nih.gov health. This FOA is intended to encourage a broader scope
of topics to be addressed with systems science
Multiple Institutes, including the National Cancer methodologies, beyond those encouraged by existing open
Institute FOAs. Research projects applicable to this FOA are those
that are either applied or basic in nature (including
Practical Interventions to Improve Medication methodological development), have a human behavioral
Adherence in Primary Care (R01) and/or social science focus, and feature systems science
PA-12-022 methodologies. NCI is interested in research projects that
Deadline: October 5, 2012 address the cause, diagnosis, prevention, and treatment of
cancer, rehabilitation from cancer, and the continuing care
"http://grants.nih.gov/grants/guide/pa-files/PA-12-022.html"
of cancer patients and the families of cancer patients. This
About FOA utilizes the R01 Research Project Grant mechanism.
This Funding Opportunity Announcement (FOA) seeks
applications that propose practical interventions to improve
adherence to medication. This FOA will support research to
test interventions with the potential to significantly improve
medication adherence in patients with chronic health
conditions in settings where primary health care is delivered
(including, dental and eye care settings). Applications may
target medication adherence in the context of treatment for
a single illness or chronic condition (e.g., hypertension) or
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 16 of 45
Period of Support Up to 5 years Multiple Institutes, including the National Cancer
Funds/Direct Costs Application budgets are not limited, Institute
but need to reflect actual needs of The Role of Microbial Metabolites in Cancer
the proposed project
Prevention and Etiology (U01)
Program Contact Kara L. Hall, PhD
PAR-11-152
6130 Executive Boulevard, Room 6134
Letter of Intent Due Date: October 15, 2012
Rockville, MD 20852
Application Due Date: November 15, 2012
(301) 594-9056
hallka@mail.nih.gov "http://grants1.nih.gov/grants/guide/pa-files/PAR-11-
152.html"
National Cancer Institute About
This Funding Opportunity Announcement (FOA)
Academic-Industrial Partnerships for Translation encourages the submission of grant applications that
of in vivo Imaging Systems for Cancer characterize the effects of microbially generated metabolites
Investigations (R01) of dietary components on host cell biology. Specifically, this
PAR-10-169 FOA seeks to characterize microbially generated
metabolites and better understand their molecular
Deadline: October 5, 2012
mechanisms of action that affect host cell
"http://grants1.nih.gov/grants/guide/pa-files/PAR-10- proliferative/apoptotic responses, cytokine production,
169.html" inflammatory and immunomodulatory effects. This FOA will
About also encourage the conduct of human intervention studies
This Funding Opportunity Announcement (FOA) that identify inter-individual variability among various racial
encourages applications from research partnerships formed and ethnic groups in the production of bacterial metabolites
by academic and industrial investigators to accelerate the and determine their efficacy in cancer prevention. This
translation of either animal or human in vivo imaging, image research is necessary to better understand the role of
guided, and/or spectroscopic systems and methods dietary components in cancer etiology, prevention, and
designed to solve targeted cancer problems for cancer cancer health disparities to identify who might benefit from
research, clinical trials, and/or clinical practice. The partners specific dietary recommendations and who might be placed
on each application will establish an inter-disciplinary, multi- at risk. One of the goals of this program will be to facilitate
institutional research team to work in a strategic alliance to interdisciplinary collaborations among scientists engaged in
implement a coherent strategy to develop and translate the nutrition, cancer prevention, cancer cell biology research,
proposed system or methods with potential for significant and cancer disparities research with those conducting
impact on preclinical, single, or multisite clinical studies. studies with gut microorganisms. All applications must
Partnerships must include at least one lead academic and include multiple principle investigators with different areas of
one lead industrial organization large or small among their expertise such as microbiology, nutrition, cancer biology,
numbers. For either preclinical or clinical research, funding analytical chemistry, or genetics. In addition, all investigators
may be requested for limited additional copies of prototype will be required to attend annual meetings with NIH
systems and methods in order to optimize and validate them personnel. Investigators may use either clinical or preclinical
across different platforms and/or research sites. This FOA approaches. This FOA will utilize the U01 Research Project
supports clinical trials that emphasize optimization and – Cooperative Agreements funding mechanism.
validation of the performance of imaging systems, including Period of Support Up to 5 years
devices, agents and/or methods. It will not support Program Contact Cindy Davis, PhD
commercial production. This FOA will utilize the NIH
6130 Executive Boulevard, Suite 3160
Research Project Grant (R01) award mechanism.
Bethesda, MD 20892-7328
Period of Support Up to 5 years
(301) 594-9692
Program Contact Houston Baker, PhD
davisci@mail.nih.gov
6130 Executive Blvd., Suite 6060
Bethesda, MD 20892-7412
Multiple Institutes, including the National Cancer
(301) 594-9117
Institute
bakerhou@mail.nih.gov
Research on Malignancies in the Context of
HIV/AIDS (R01)
PA-10-290
Deadline: September 7, 2012
"http://grants.nih.gov/grants/guide/pa-files/PA-10-290.html"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 17 of 45
About Period of Support Up to 2 years
This Funding Opportunity Announcement (FOA) Funds/Direct Costs $275,000 over an R21 two-year
encourages applications from institutions/organizations that period, with up to $200,000 in direct
propose to continue advancing our understanding of the costs allowed in any single year
risks, development, progression, diagnosis, and treatment Program Contact Elizabeth Read-Connole, PhD
of malignancies observed in individuals with an underlying
Human Immunodeficiency (HIV) infection or Acquired 6130 Executive Boulevard, Room 5016
Immune Deficiency Syndrome (AIDS). The NCI and NIDCR Bethesda, MD 20892-7398
seek to encourage research in areas such as the study of (301) 496-6085
the etiologic factors, cofactors, immunopathogenesis, bconnole@mail.nih.gov
diagnosis, and consequences of both AIDS-defining and
non-AIDS defining malignancies in diverse populations in
Multiple Institutes, including the National Cancer
the context of an underlying HIV infection. This FOA invites
research efforts that will: (i) provide information on the Institute
clinical outcomes of such cancers in the HIV-infected Specialized Programs of Research Excellence
population; and (ii) identify specific contributions resulting (SPOREs) in Human Cancer for Years 2010, 2011
from HIV infection and its potential interaction with other and 2012 (P50)
pathogens for the development and pathogenesis of these
cancers. This FOA will utilize the Research Project Grant PAR-10-003
(R01) mechanism. Deadline: September 20, 2012
Period of Support Up to 5 years "http://grants.nih.gov/grants/guide/pa-files/PAR-10-003.html"
Program Contact Elizabeth Read-Connole, PhD About
6130 Executive Boulevard, Room 5016 The program will support state-of-the-art investigator-
Bethesda, MD 20892-7398 initiated research that will contribute to improved prevention,
early detection, diagnosis, and treatment of an organ-
(301) 496-6085 specific cancer (or a related group of cancers). Specialized
bconnole@mail.nih.gov Programs of Research Excellence (SPOREs) are expected
not only to conduct a wide spectrum of research activities,
Multiple Institutes, including the National Cancer but also to contribute significantly to the development of
Institute specialized research COREs, improved research model
systems, and collaborative research projects with other
Research on Malignancies in the Context of institutions. The research supported through this program
HIV/AIDS (R21) must be translational in nature and must always be based
PA-10-291 upon knowledge of human biology stemming from research
Deadline: September 7, 2012 using cellular, molecular, structural, biochemical, and/or
genetic experimental approaches. In addition, SPOREs
"http://grants.nih.gov/grants/guide/pa-files/PA-10-291.html"
must include both a Developmental Research Program for
About pilot studies and a Career Development Program to foster
This Funding Opportunity Announcement (FOA) careers in organ-based translational science. This Funding
encourages applications from institutions/organizations that Opportunity Announcement (FOA) will utilize the NIH
propose to continue advancing our understanding of the Specialized Center Grant (P50) mechanism.
risks, development, progression, diagnosis, and treatment Period of Support Up to 5 years
of malignancies observed in individuals with an underlying
Funds/Direct Costs Up to $2.5M total costs per year
Human Immunodeficiency (HIV) infection or Acquired
Immune Deficiency Syndrome (AIDS). Research is Program Contact Toby T. Hecht, PhD
encouraged in areas such as the study of the etiologic 6116 Executive Boulevard, Suite 700
factors, cofactors, immunopathogenesis, diagnosis, and Bethesda, MD 20892-8347
consequences of both AIDS-defining and non-AIDS defining (301) 496-8528
malignancies in diverse populations in the context of an hechtt@mail.nih.gov
underlying HIV infection. This FOA invites research efforts
that will: (i) provide information on the clinical outcomes of
such cancers in the HIV-infected population; and (ii) identify National Cancer Institute
specific contributions resulting from HIV infection and its National Cancer Institute (NCI) Cancer Education
potential interaction with other pathogens for the and Career Development Program (R25)
development and pathogenesis of these cancers. This FOA
will utilize the R21 Exploratory/Developmental Research PAR-10-165
Grant Award mechanism. Deadline: September 25, 2012
"http://grants1.nih.gov/grants/guide/pa-files/PAR-10-
165.html"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 18 of 45
About Multiple Institutes, including the National Cancer
The purpose of the NCI Cancer Education and Career Institute
Development Program (CECDP) is to support the
development and implementation of institutional curriculum-
Ethical Legal and Social Implications (ELSI) of
dependent research education and career development Genomic Research Regular Research Program
programs to train predoctoral and postdoctoral individuals in (R01)
cancer research settings that are highly interdisciplinary and PA-11-250
collaborative. Examples of interdisciplinary/collaborative Deadline: October 5, 2012
areas of cancer research that are particularly applicable to
the intent of the CECDP are cancer prevention and control, "http://grants.nih.gov/grants/guide/pa-files/PA-11-250.html"
behavioral and population sciences, nutrition, imaging, and About
molecular diagnosis. Institutional training programs in these This Funding Opportunity Announcement (FOA)
highly interdisciplinary areas of cancer research require encourages applications that propose to study the ethical,
sustained leadership, dedicated faculty time, specialized legal and social implications (ELSI) of human genome
curriculum development and implementation, research. The NCI is interested in empirical research that
interdisciplinary research environments, and more than one focuses on the ethical, legal and social issues related to
mentor per program participant/trainee to achieve their heritable cancer syndromes. Study of the psycho-social and
objectives. The goal is to develop a cadre of scientists who behavioral impact on affected individuals, their families and
are prepared to conduct cancer research in interdisciplinary populations and research that takes into consideration the
and highly collaborative team-oriented environments. This perspectives of diverse racial, ethnic and socioeconomic
FOA makes an NCI-specific use of the NIH Education R25 backgrounds, as well as children, older adults and people
grant mechanism. with disabilities is highly desirable. The ultimate goal of this
Period of Support Up to 5 years research will be to improve outcomes related to the
diagnosis of heritable cancer syndromes. This FOA will
Funds/Direct Costs Direct costs for year one of new (i.e.,
utilize the NIH Research Project Grant (R01) award
Type 1) applications, during which
mechanism.
no participant costs are allowed,
must stay below $100,000 Period of Support Up to 5 years
Program Contact Dorkina Myrick, MD, PhD Program Contact Laura Buccini
6116 Executive Boulevard, Suite 7033 (301) 435-2384
Bethesda, MD 20892-8346 laura.buccini@nih.gov
(301) 496-8580
myrickd@mail.nih.gov Multiple Institutes, including the National Cancer
Institute
National Cancer Institute Research on Ethical Issues in Biomedical, Social
National Cancer Institute Program Project and Behavioral Research (R01)
Applications (P01) PA-11-180
PAR-12-005 Deadline: October 5, 2012
Deadline: September 25, 2012 "http://grants.nih.gov/grants/guide/pa-files/PA-11-180.html"
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-005.html" About
About The purpose of this Funding Opportunity Announcement
Proposed program projects may address any of the broad (FOA) is to support applications that propose to study high
areas of cancer research, including (but not limited to) priority bioethical challenges and issues associated with the
cancer biology, cancer treatment, cancer diagnosis, cancer types of biomedical, social, and behavioral research
prevention, and cancer control. Basic, translational, clinical, supported by the participating NIH Institutes/Centers. The
and/or population based studies in all of these research following specific bioethics topics will be given the highest
areas are appropriate. Each Program Project application priority for consideration. These are organized into seven
must consist of at least three component projects. The categories: 1) ethical considerations of new and emerging
component projects must share a common central theme, technologies; 2) research study design issues; 3) issues
focus, and/or overall objective. Letters of intent are due 30 associated with therapeutic misconception and the interface
days prior to the anticipated application due date(s). This between treatment and research; 4) research involving
Funding Opportunity Announcement (FOA) will utilize the vulnerable populations and urgent situations; 5) research
Research Program Projects (P01) grant mechanism. with existing specimens, data, and health information; 6)
dissemination and translation of research findings; and 7)
Period of Support Up to 5 years oversight of research. This FOA will utilize the R01
Program Contact Referral Officer Research Project Grant mechanism.
6116 Executive Blvd., Room 8040
Bethesda, MD 20892-8329
(301) 496-3428
ncirefof@dea.nci.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 19 of 45
Period of Support Up to 5 years Period of Support Up to 3 years
Program Contact Kim Witherspoon Program Contact Suzanne Forry-Schaudies, PhD
Bethesda (301) 435-9147
(301) 496-8866 forryscs@mail.nih.gov
kw265c@nih.gov
Multiple Institutes, including the National Cancer
Multiple Institutes, including the National Cancer Institute
Institute Mechanisms of Alcohol-Associated Cancers (R01)
Translational Research at the Aging/Cancer PA-12-146
Interface (TRACI) (R01) Deadline: October 5, 2012
PA-12-136 "http://grants.nih.gov/grants/guide/pa-files/PA-12-146.html"
Deadline: October 5, 2012 About
"http://grants.nih.gov/grants/guide/pa-files/PA-12-136.html" This Funding Opportunity Announcement (FOA) invites
About applications from researchers with broad ranges of
This Funding Opportunity Announcement (FOA) expertise to study the mechanisms by which alcohol
encourages translational research proposals in the increases cancer risk. Target sites for alcohol-related
overlapping areas of human aging and cancer, linking basic carcinogenesis include the oral cavity, pharynx, esophagus,
and clinical research relevant to the care of older cancer larynx, breast, liver, and colon. A better understanding of the
patients through both bench-to-bedside and bedside-to- molecular basis by which alcohol increases cancer risk
bench approaches. Ultimately, information from the could lead to improved therapeutic approaches and
research supported by this initiative should improve the preventative strategies and would provide guidance on safe
health and well-being of elderly patients at risk for, or levels of alcohol consumption. The goal of this program
diagnosed with, cancer and decrease the functional announcement is to stimulate a broad range of research into
impairment and morbidity associated with cancer in this the mechanisms by which alcohol contributes to
population. This FOA utilizes the Research Project Grant carcinogenesis. This FOA utilizes the NIH Research Project
(R01) grant mechanism. Grant (R01) award mechanism.
Period of Support Up to 5 years Period of Support Up to 5 years
Funds/Direct Costs Application budgets are not limited, Funds/Direct Costs Application budgets are not limited,
but need to reflect actual needs of but need to reflect actual needs of
the proposed project. the proposed project.
Program Contact T. Kevin Howcroft, PhD Program Contact Sharon Ross, PhD
6130 Executive Boulevard 6130 Executive Boulevard, Room 3157
Rockville, MD 20892 Rockville, MD 20852
(301) 496-7815 (301) 594-7547
howcrofk@mail.nih.gov rosssha@mail.nih.gov
Multiple Institutes, including the National Cancer Multiple Institutes, including the National Cancer
Institute Institute
Solicitation of Validated Hits for the Discovery of Nanoscience and Nanotechnology in Biology and
in vivo Chemical Probes (R01) Medicine (R01)
PAR-12-060 PA-11-148
Deadline: October 5, 2012 Deadline: October 5, 2012
'http://grants1.nih.gov/grants/guide/pa-files/PAR-12- "http://grants.nih.gov/grants/guide/pa-files/PA-11-148.html"
060.html" About
About This initiative encourages applications that apply
This Funding Opportunity Announcement (FOA) intends to nanoscience and nanotechnology approaches to address
support investigators who have interest and capability to join problems in biology and medicine. The purpose of this
efforts for the discovery of in vivo chemical probes. It is Funding Opportunity Announcement (FOA) is to provide
expected that applicants will have in hand the starting support for cutting-edge nanoscience and nanotechnology
compounds (“validated hits”) for chemical optimization and research that can lead to biomedical breakthroughs and
bioassays for testing new analog compounds. Through this new investigations into the diagnosis, treatment and
FOA, the NCI is particularly interested in validated hits for management of an array of diseases and traumatic injuries.
targets that address unmet needs in the prevention, Nanoscience and nanotechnology have the capacity to drive
treatment, or diagnosis of cancer. Strategies that include a new wave of medical innovation through the engineering
testing of in vivo chemical probe activity in primary human of bioactive nanoscale structures, processes and systems
tumor cells are encouraged. This FOA utilizes the NIH R01 based on the advancement of our understanding of biology
Research Project Grant mechanism. at the nanoscale. Therefore, this FOA will also support
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 20 of 45
research projects that develop new or improved tumoricidal activity of NK cells. Research projects that are
nanotechnology and nanoscience-based tools, methods, appropriate to this FOA should focus on defining the
concepts, and devices that lead to a better understanding of minimum quantity and duration of exposure to specific
basic biology in addition to conducting translational dietary components to modulate tumoricidal activity of NK
biomedical studies. This FOA will utilize the R01 Research cells for cancer prevention and the underlying
Project Grant mechanism. mechanism(s) accounting for this response. This FOA will
Period of Support Up to 5 years utilize the NIH research project R01 grant mechanism.
Program Contact Piotr Grodzinski Period of Support Up to 5 years
(301) 594-4177 Program Contact Young S. Kim, PhD
grodzinp@mail.nih.gov 6130 Executive Blvd., Room 3156
Bethesda, MD 20892-7328
Multiple Institutes, including the National Cancer (301) 496-0126
Institute yk47s@nih.gov
The Effect of Racial and Ethnic
Discrimination/Bias on Health Care Delivery (R01) National Cancer Institute
PA-11-162 Validation of Molecular Diagnostics to Predict
Deadline: October 5, 2012 Patient Outcomes Using Specimens from Multi-
"http://grants.nih.gov/grants/guide/pa-files/PA-11-162.html" Site Cancer Trials (R01)
PA-12-013
About
This Funding Opportunity Announcement (FOA) Deadline: October 5, 2012
encourages the submission of research project grant "http://grants.nih.gov/grants/guide/pa-files/PA-12-013.html"
applications that propose to: (1) improve the measurement About
of racial/ethnic discrimination in health care delivery This Funding Opportunity Announcement (FOA)
systems through improved instrumentation, data collection, encourages applications to validate the clinical utility of new
and statistical/analytical techniques; (2) to enhance molecular diagnostics for determining prognosis or
understanding of the influence of racial/ethnic discrimination predicting response to therapy or toxicity for cancer. This
in health care delivery and its association with disparities in program will support research projects to improve clinical
disease incidence, treatment, and outcomes among decision-making in the care of cancer patients and as such
disadvantaged racial/ethnic minority groups: and (3) to will support studies that use tumor specimens linked to
reduce the prevalence of racial/ethnic health disparities specific treatment and clinical outcome information. This
through the development of interventions to reduce the FOA is not appropriate for molecular diagnostics discovery
influence of racial/ethnic discrimination on health care projects. This FOA utilizes the NIH Research Project Grant
delivery systems in the United States (U.S.). This FOA will (R01) mechanism.
utilize the NIH Research Project Grant (R01) award
mechanism. Period of Support Up to 5 years
Program Contact Magdalena Thurin, PhD
Period of Support Up to 5 years
6130 Executive Boulevard, Room
Program Contact Vickie L. Shavers, PhD
6035A
6130 Executive Blvd., Room 4005
Bethesda, MD 20892-7420
Bethesda, MD 20892-7344
(301) 496-1591
(301) 594-1725
thurinm@mail.nih.gov
shaversv@mail.nih.gov
National Cancer Institute
Multiple Institutes, including the National Cancer
Institute Mitochondria in Cancer Epidemiology, Detection,
Diagnosis and Prognosis (R01)
Enhancing Tumoricidal Activity of Natural Killer
PA-11-073
(NK) Cells by Dietary Components for Cancer
Deadline: October 5, 2012
Prevention (R01)
"http://grants.nih.gov/grants/guide/pa-files/PA-11-073.html"
PA-11-160
Deadline: October 5, 2012 About
This Funding Opportunity Announcement (FOA)
"http://grants1.nih.gov/grants/guide/pa-files/PA-11-160.html"
encourages applications that propose to develop and
About validate new mitochondrial-related biomarkers for cancer
This Funding Opportunity Announcement (FOA) promotes early detection, diagnosis, prognosis, risk assessment, and
research to characterize the significance of dietary response to preventive and ameliorative treatments. Using
components in regulating the tumoricidal activity of natural the NIH Research Project Grant (R01) funding mechanism,
killer (NK) cells for cancer prevention. Specifically, this FOA this FOA focuses on discrete, specified, circumscribed
encourages studies that can establish the physiological projects based upon strong preliminary data.
significance of dietary components in modulating the
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 21 of 45
Period of Support Up to 5 years intervention studies. This FOA utilizes the NIH Exploratory /
Program Contact Mukesh Verma, PhD Developmental (R21) award mechanism.
6130 Executive Boulevard, Room 5100 Period of Support Up to 2 years
Bethesda, MD 20892-7324 Funds/Direct Costs $275,000 direct costs for entire
(301) 594-7344 period of support, up to $200,000
vermam@mail.nih.gov direct costs allowed in any single year
Program Contact Barbara Liesenfeld
Multiple Institutes, including the National Cancer 6120 Executive Boulevard, Room 243
Institute Bethesda, MD 20892-7150
(301) 496-3265
Ruth L. Kirschstein National Research Service
liesenfb@mail.nih.gov
Award (NRSA) Institutional Research Training
Grants (T32)
Multiple Institutes, including the National Cancer
PA-11-184
Institute
Deadline: September 25, 2012
Behavioral Interventions to Address Multiple
"http://grants.nih.gov/grants/guide/pa-files/PA-11-184.html"
Chronic Health Conditions in Primary Care (R01)
About
PA-12-024
The National Institutes of Health (NIH) will award Ruth L.
Kirschstein National Research Service Award (NRSA) Deadline: October 5, 2012
Institutional Research Training Grants (T32) to eligible "http://grants.nih.gov/grants/guide/pa-files/PA-12-024.html"
institutions as the primary means of supporting predoctoral About
and postdoctoral research training. The objective of the T32 This Funding Opportunity Announcement (FOA) seeks
program is to prepare qualified individuals for careers that applications that propose to use a common conceptual
have a significant impact on the health-related research model to develop behavioral interventions to modify health
needs of the Nation. The grant offsets the cost of stipends, behaviors and improve health outcomes in patients with
tuition and fees, and training related expenses including comorbid chronic diseases and health conditions.
health insurance for the appointed trainees in accordance Specifically, this FOA will support research in primary care
with the approved NIH support levels. The NCI does not that uses a multi-disease care management approach to
support short-term research training positions under the T32 behavioral interventions with high potential impact to
mechanism. Trainee appointments are made in 12 month improve patient-level health outcomes for individuals with
increments. three or more chronic health conditions. The proposed
Period of Support Up to 5 years approach must modify behaviors using a common approach
Program Contact Nancy C. Lohrey, MS, MT-ASCP, MS rather than administering a distinct intervention for each
6116 Executive Boulevard, Room 7019 targeted behavior and/or condition. Diseases and health
conditions can include, but are not limited to: mental health
Bethesda, MD 20892-8346 disorders (e.g., depression), diabetes, smoking, obesity,
(301) 496-8580 chronic pain, alcohol and substance abuse and
lohreyn@mail.nih.gov dependence, chronic obstructive pulmonary disorder,
cancer and hypertension. This FOA utilizes the NIH
Multiple Institutes, including the National Cancer Research Project Grant (R01) mechanism.
Institute Period of Support Up to 5 years
Nutrition and Alcohol-Related Health Outcomes Funds/Direct Costs Application budgets are not limited,
(R21) but need to reflect actual needs of
the proposed project
PA-10-241
Program Contact Veronica Chollette
Deadline: October 16, 2012 (301) 435-2837
"http://grants.nih.gov/grants/guide/pa-files/PA-10-241.html" cholletv@exchange.nih.gov
About
This Funding Opportunity Announcement (FOA) Multiple Institutes, including the National Cancer
encourages research grant applications from Institute
institutions/organizations that propose to examine
associations between nutrition and alcohol-related health Translational Research at the Aging/Cancer
outcomes in humans and animal models. The goal of this Interface (TRACI) (R21)
program announcement is to stimulate a broad range of PA-12-135
research on the role of nutrition in the development, Deadline: October 16, 2012
prevention, and treatment of a variety of alcohol-related
health outcomes including alcohol dependence and "http://grants.nih.gov/grants/guide/pa-files/PA-12-135.html"
psychiatric co-morbidities, chronic and acute diseases, and
organ function and damage. Study designs may include
biomedical research, epidemiologic approaches, and
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 22 of 45
About Multiple Institutes, including the National Cancer
This Funding Opportunity Announcement (FOA) Institute
encourages translational research proposals in the
overlapping areas of human aging and cancer, linking basic Pilot and Feasibility Clinical Research Studies in
and clinical research relevant to the care of older cancer Digestive Diseases and Nutrition (R21)
patients through both bench-to-bedside and bedside-to- PA-12-139
bench approaches. Ultimately, information from the Deadline: October 16, 2012
research supported by this initiative should improve the
"http://grants.nih.gov/grants/guide/pa-files/PA-12-139.html"
health and well-being of elderly patients at risk for, or
diagnosed with, cancer and decrease the functional About
impairment and morbidity associated with cancer in this This Funding Opportunity Announcement (FOA)
population. This FOA utilizes the NIH encourages pilot and feasibility clinical and epidemiological
Exploratory/Developmental (R21) grant mechanism. research studies of new therapies or means of health
Period of Support Up to 2 years promotion and prevention of digestive and liver diseases
and nutritional disorders associated with digestive and liver
Funds/Direct Costs $275,000 direct costs for period of
diseases. This FOA wutilizes the NIH
support, up to $200,000 direct costs
Exploratory/Developmental (R21) grant mechanism.
allowed in any single year
Program Contact T. Kevin Howcroft, PhD Period of Support Up to 2 years
6130 Executive Boulevard Funds/Direct Costs $275,000 direct costs for entire
period of support, up to $200,000
Rockville, MD 20892
direct costs allowed in any single year
(301) 496-7815
Program Contact Maria Agelli, MD, MS, FACPM
howcrofk@mail.nih.gov
6130 Executive Boulevard, Room 3104
Bethesda, MD 20892-7341
Multiple Institutes, including the National Cancer
(301) 451-3993
Institute
ma215e@nih.gov
Exploratory/Developmental Clinical Research
Grants in Obesity (R21) National Cancer Institute
PA-12-179 Biomarkers for Early Detection of Hematopoietic
Deadline: October 16, 2012 Malignancies (R21)
"http://grants.nih.gov/grants/guide/pa-files/PA-12-179.html"
PA-12-220
About Deadline: October 16, 2012
This FOA encourages research grant applications from "http://grants.nih.gov/grants/guide/pa-files/PA-12-220.html"
institutions/organizations that propose to conduct
exploratory/developmental clinical studies that will About
accelerate the development of effective interventions for This Funding Opportunity Announcement (FOA)
prevention or treatment of overweight or obesity in adults encourages research projects for the development and
and/or children. Exploratory epidemiological research with a validation of biomarkers for: a) early detection, prediction of
goal of informing translational/clinical research will also be progression, and recurrence of hematopoietic malignancies,
supported within this program. The types of research especially in high-risk individuals; and, b) for risk
applications which NCI is interested in supporting include assessment of primary and secondary hematopoietic
human intervention studies utilizing bioactive components malignancies. This FOA also encourages the development
(e.g., tea polyphenols, calcium) or variation in diet and improvement of specific technologies and methods for
composition strategies that evaluate weight change in quantitative detection of novel biomarkers associated with
populations of interest to NCI. Such populations include hematopoietic malignancies. This program utilizes the NIH
individuals with a genetic propensity for cancer as well as Exploratory/Developmental (R21) grant mechanism.
those with cancer or those at risk for recurrence of cancer. Period of Support Up to 2 years
This FOA utilizes the NIH Exploratory/Developmental (R21) Funds/Direct Costs $275,000 direct costs for entire
grant mechanism. period of suppport, up to $200,000
Period of Support Maximum of 2 years direct costs allowed in any single year
Funds/Direct Costs $275,000 direct costs over entire Program Contact Lynn Sorbara
period of support, with up to 6130 Executive Boulevard, Room 3137
$200,000 in direct costs allowed in Bethesda, MD 20892-7362
any single year
(301) 435-0584
Program Contact Sharon A. Ross, PhD
lynns@mail.nih.gov
6130 Executive Boulevard, Room 3175
Bethesda, MD 20892-7328
(301) 594-7547
rosssha@mail.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 23 of 45
National Cancer Institute National Cancer Institute
Identifying Non-coding RNA Targets for Early Development, Application, and Evaluation of
Detection of Cancer (R21) Prediction Models for Cancer Risk and Prognosis
PA-12-214 (R21)
Deadline: October 16, 2012 PA-10-026
"http://grants1.nih.gov/grants/guide/pa-files/PA-12-214.html" Deadline: October 16, 2012
About "http://grants1.nih.gov/grants/guide/pa-files/PA-10-026.html"
This Funding Opportunity Announcement (FOA) About
encourages research projects on non-coding RNAs The sponsor invites research applications from clinicians,
(ncRNAs) and their targets in preneoplastic lesions and epidemiologists, geneticists, statisticians, and translational
early stage cancers. This FOA also encourages research researchers working in the field of cancer control and
projects to assess the usefulness of stable microRNAs prevention to improve existing models for cancer risk and
(miRNAs) and ncRNAs to predict progression to cancer and prognosis by developing innovative research projects that
as biomarkers for early cancer detection and screening. use existing data; develop new models for cancer risk and
Building on both basic and biomarker research on prognosis; and validate new models and evaluate their utility
microRNAs (miRNA), this FOA will further promote research in research and clinic settings. This FOA encourages
on all classes of ncRNAs and support the translation of applications for research projects to develop, apply, and
stable miRNAs into cancer screening or diagnostic tests. evaluate new and existing cancer risk and prognostic
This Funding Opportunity Announcement (FOA) utilizes the prediction models for use by researchers, clinicians, and the
NIH Exploratory/Developmental (R21) grant mechanism. general public. This FOA is designed to provide a
Period of Support Up to 2 years mechanism of support for investigators to address two
Funds/Direct Costs $275,000 direct costs over entire major challenges in model development, which are:
period of support, up to $200,000 integrating diverse types of data (e.g., clinical, demographic,
direct costs allowed in any single year pathologic, environmental, epidemiologic, outcomes, and
genetic data from varied data marts or warehouses); and
Program Contact Wendy Wang, PhD, MSc ensuring adequate validation (i.e., using multiple separate
6130 Executive Boulevard, Room 3138 populations to define sensitivity, specificity, and positive and
Bethesda, MD 20892-7362 negative predictive values). This program utilizes the NIH
(301) 594-7607 Exploratory/Developmental (R21) grant mechanism.
wangw@mail.nih.gov Period of Support Up to 2 years
Funds/Direct Costs $275,000 direct costs for entire
Multiple Institutes, including the National Cancer period of support, up to $200,000
Institute direct costs allowed in any single year
Biomarkers of Infection-Associated Cancers (R21) Program Contact Andrew N. Freedman, PhD
6130 Executive Boulevard, EPN
PA-11-159
Room 4005
Deadline: October 16, 2012
Bethesda, MD 20892-7344
"http://grants.nih.gov/grants/guide/pa-files/PA-11-159.html"
(301) 435-6819
About freedmaa@mail.nih.gov
This Funding Opportunity Announcement (FOA)
encourages the submission of applications that propose to Multiple Institutes, including the National Cancer
identify biomarkers for cancers where the etiology of the
disease is attributed to infectious agents. This FOA utilizes Institute
the NIH Exploratory/Developmental Grant (R21) mechanism. Obesity Policy Research: Evaluation and
Period of Support Up to 2 years Measures (R21)
Funds/Direct Costs $275,000 direct costs for entire PA-10-028
period of support, up to $200,000 Deadline: October 16, 2012
direct costs allowed in any single year "http://grants.nih.gov/grants/guide/pa-files/PA-10-028.html"
Program Contact Kark Krueger, PhD
About
6130 Executive Boulevard, Room 3147 This Funding Opportunity Announcement (FOA),
Bethesda, MD 20892-7362 encourages Exploratory/Developmental Grant (R21)
(301) 435-1594 applications that propose to: (1) conduct evaluation
kruegerk@mail.nih.gov research on obesity-related natural experiments (defined
here as community and other population-level public policy
interventions that may affect diet and physical activity
behavior), and/or (2) develop and/or validate relevant
community-level measures (instruments and methodologies
to assess the food and physical activity environments at the
community level). The overarching goal of this FOA is to
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 24 of 45
inform public policy and research relevant to (1) diet and About
physical activity behavior, and (2) weight and health This Funding Opportunity Announcement (FOA)encourages
outcomes of Americans. The R21 grant mechanism is research applications that propose to evaluate profiles of
intended to encourage exploratory/developmental research methylation, histone modifications and micro RNA (miRNA)
by providing support for the early and conceptual stages of and their association with risk of developing cancer in
project development. different populations. The overarching goal of this FOA is to
Period of Support Up to 2 years provide support for population based studies to define the
role of epigenetic markers (methylation, histone and micro
Funds/Direct Costs $275,000 direct costs for entire RNA profiles) changes to understand cancer etiology. This
period of support, up to $200,000
program utilizes the NIH Exploratory/Developmental (R21)
direct costs allowed in any single year
grant mechanism.
Program Contact Robin McKinnon, PhD, MPA
Period of Support Up to 2 years
6130 Executive Boulevard
Funds/Direct Costs $275,000 direct costs for entire
Bethesda, MD 20892-7324
period of support, up to $200,000
(301) 594-3599 direct costs allowed in any single year
mckinnonr@mail.nih.gov Program Contact Mukesh Verma, PhD
6130 Executive Boulevard, Room 5100
Multiple Institutes, including the National Cancer Bethesda, MD 20892-7324
Institute (301) 594-7344
Obesity Policy Research: Evaluation and vermam@mail.nih.gov
Measures (R03)
PA-10-029 National Cancer Institute
Deadline: October 16, 2012 Validation of Molecular Diagnostics to Predict
"http://grants.nih.gov/grants/guide/pa-files/PA-10-029.html" Patient Outcomes Using Specimens from Multi-
About Site Cancer Trials (R21)
This Funding Opportunity Announcement (FOA) PA-12-014
encourages Small Research Grant (R03) applications that Deadline: October 16, 2012
propose to: (1) conduct evaluation research on obesity-
"http://grants1.nih.gov/grants/guide/pa-files/PA-12-014.html"
related “natural experiments” (defined here as community
and other population-level public policy interventions that About
may affect diet and physical activity behavior), and/or (2) This Funding Opportunity Announcement (FOA)
develop and/or validate relevant community-level measures encourages the submission of applications to validate the
(instruments and methodologies to assess the food and clinical utility of new molecular diagnostics for determining
physical activity environments at the community level). The prognosis or predicting response to therapy or toxicity for
overarching goal of this FOA is to inform public policy cancer. This program will support pilot research projects to
relevant to diet and physical activity behavior, and weight improve clinical decision-making in the care of cancer
and health outcomes of Americans. The R03 grant patients and as such will support studies that use tumor
mechanism supports different types of projects including specimens linked to specific treatment and clinical outcome
pilot and feasibility studies; secondary analysis of existing information. This FOA is not appropriate for molecular
data; small, self-contained research projects; development diagnostics discovery projects. This FOA will utilize the NIH
of research methodology; and development of new research Exploratory/Developmental Grant (R21) mechanism.
technology. The R03 is intended to support small research Period of Support Up to 2 years
projects that can be carried out in a short period of time with
limited resources. Funds/Direct Costs Up to $275,000 for entire period of
support, with no more than $200,000
Period of Support Up to 2 years requested in any single year
Funds/Direct Costs $50,000 direct costs per year Program Contact Magdalena Thurin, PhD
Program Contact Robin McKinnon, PhD, MPA 6130 Executive Boulevard, Room
6130 Executive Boulevard 6035A
Bethesda, MD 20892-7324 Bethesda, MD 20892-7420
(301) 594-3599 (301) 496-1591
mckinnonr@mail.nih.gov thurinm@mail.nih.gov
National Cancer Institute
Epigenetic Approaches in Cancer Epidemiology
(R21)
PA-10-032
Deadline: October 16, 2012
"http://grants1.nih.gov/grants/guide/pa-files/PA-10-032.html"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 25 of 45
Multiple Institutes, including the National Cancer Period of Support Up to 2 years
Institute Funds/Direct Costs $275,000 direct costs for entire
Advancing Novel Science in Women’s Health period of support, up to $200,000
direct costs allowed in any single year
Research (ANSWHR) (R21)
Program Contact Young S. Kim, PhD
PAS-10-226
6130 Executive Blvd., Room 243
Deadline: October 16, 2012
Bethesda, MD 20892-7328
"http://grants.nih.gov/grants/guide/pa-files/PAS-10-226.html"
(301) 496-0126
About yk47s@nih.gov
The purpose of this Funding Opportunity Announcement
(FOA) is to promote innovative, interdisciplinary research
that will advance new concepts in women’s health research
Multiple Institutes, including the National Cancer
and the study of sex/gender differences. Recent research Institute
reports have established the importance of studying issues Identification and Characterization of Molecular
specific to women, including the scientific and clinical Targets Within the mTOR Pathway With Potential
importance of analyzing data separately for females and to Impact Healthspan and Lifespan (R21)
males. The Office of Research on Women’s Health
(ORWH) is particularly interested in encouraging extramural PA-10-164
investigators to undertake new interdisciplinary research to Deadline: October 16, 2012
advance studies on how sex and gender factors affect "http://grants1.nih.gov/grants/guide/pa-files/PA-10-164.html"
women's health; however, applications in all areas of
About
women’s health and/or sex/gender research are invited.
This FOA will utilize the NIH Exploratory/Developmental This Funding Opportunity Announcement (FOA)
(R21) award mechanism. encourages grant applications focused on identifying and
characterizing dietary constituents that modulate the mTOR
Period of Support Up to 2 years pathway and promote cancer prevention. Identification and
Funds/Direct Costs $275,000 direct costs over a two- characterization of targets can utilize a wide range of
year period, with up to $200,000 in approaches, including medicinal chemistry, in vitro assays,
direct costs allowed in any single year and studies in lower organisms or mammalian models. This
Program Contact Crystal Wolfrey FOA utilizes the NIH Exploratory/Developmental (R21)
6120 Executive Blvd., Suite 243 award mechanism.
Bethesda, MD 20892-7150 Period of Support Up to 2 years
(301) 496-8634 Funds/Direct Costs $275,000 direct costs for entire
wolfreyc@mail.nih.gov period of support, up to $200,000
direct costs allowed in any single year
Program Contact Sharon Ross, PhD, MPH
Multiple Institutes, including the National Cancer
Institute 6130 Executive Boulevard, Suite 3157
Bethesda, MD 20892-7328
Enhancing Tumoricidal Activity of Natural Killer
(301) 594-7547
(NK) Cells by Dietary Components for Cancer
rosssha@mail.nih.gov
Prevention (R21)
PA-11-161 Multiple Institutes, including the National Cancer
Deadline: October 16, 2012 Institute
"http://grants1.nih.gov/grants/guide/pa-files/PA-11-161.html"
Spatial Uncertainty: Data, Modeling, and
About Communication (R21)
This Funding Opportunity Announcement (FOA) promotes
PA-11-239
research to characterize the significance of dietary
components in regulating the tumoricidal activity of natural Deadline: October 16, 2012
killer (NK) cells for cancer prevention. Specifically, this FOA "http://grants.nih.gov/grants/guide/pa-files/PA-11-239.html"
encourages studies that can establish the physiological About
significance of dietary components in modulating the The purpose of this Funding Opportunity Announcement
tumoricidal activity of NK cells. Research projects that are (FOA) is to support innovative research that identifies
appropriate to this FOA should focus on defining the sources of spatial uncertainty (i.e., inaccuracy or instability
minimum quantity and duration of exposure to specific of spatial or geographic information) in public health data,
dietary components to modulate tumoricidal activity of NK incorporates the inaccuracy or instability into statistical
cells for cancer prevention and the underlying methods, and develops novel tools to visualize the nature
mechanism(s) accounting for this response. This FOA will and consequences of spatial uncertainty. The National
utilize the NIH Exploratory/Developmental Grant (R21) Cancer Institute (NCI) is interested in general methodology
mechanism. of spatial statistical models and visualization tools that are
applicable to disease control and prevention especially as
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 26 of 45
related to cancer and cancer patients. This FOA utilizes the and community environment and body weight. The R03
R21 Exploratory/Developmental Research Grant Award grant mechanism supports different types of projects
mechanism. including pilot and feasibility studies; secondary analysis of
existing data; small, self-contained research projects;
Period of Support Up to 2 years
development of research methodology; and development of
Funds/Direct Costs $275,000 direct costs over entire new research technology. The R03 is intended to support
period of support small research projects that can be carried out in a short
Program Contact Li Zhu, PhD period of time with limited resources.
(301) 594-6546
Period of Support Up to 2 years
li.zhu@nih.gov
Funds/Direct Costs $50,000 direct costs per year
Program Contact Tanya Agurs-Collins, PhD, RD
Multiple Institutes, including the National Cancer
6130 Executive Boulevard,Room 4084
Institute
Bethesda, MD 20892-7324
Spatial Uncertainty: Data, Modeling, and (301) 594-6637
Communication (R03) collinsta@mail.nih.gov
PA-11-240
Deadline: October 16, 2012 Multiple Institutes, including the National Cancer
"http://grants.nih.gov/grants/guide/pa-files/PA-11-240.html" Institute
About Solicitation of Assays for High Throughput
The purpose of this Funding Opportunity Announcement Screening (HTS) to Discover Chemical Probes
(FOA) is to support innovative research that identifies (R21)
sources of spatial uncertainty (i.e., inaccuracy or instability
of spatial or geographic information) in public health data, PAR-12-059
incorporates the inaccuracy or instability into statistical Deadline: October 16, 2012
methods, and develops novel tools to visualize the nature "http://grants1.nih.gov/grants/guide/pa-files/PAR-12-
and consequences of spatial uncertainty. The National 059.html"
Cancer Institute (NCI) is interested in general methodology About
of spatial statistical models and visualization tools that are
This Funding Opportunity Announcement (FOA)
applicable to disease control and prevention especially as
encourages investigators to form collaborations with an
related to cancer and cancer patients. This FOA utilizes the
established academic, nonprofit, or commercial high
NIH R03 Small Grant Program mechanism.
throughput screening (HTS) facility that has the requisite
Period of Support Up to 2 years expertise and experience to implement HTS-ready assays
Funds/Direct Costs $50,000 direct costs per year for the discovery and development of small molecule
Program Contact Li Zhu, PhD chemical probes. Through this FOA, the NCI is interested in
(301) 594-6546 high throughput screens intended to identify small
molecules for use in elucidating molecular, cellular, or in
li.zhu@nih.gov vivo mechanisms or processes of probable or known
importance to cancer biology, and for use in developing
Multiple Institutes, including the National Cancer strategies for cancer prevention, diagnosis, treatment or
Institute clinical monitoring of treatment. Screens may be
School Nutrition and Physical Activity Policies, biochemical, cellular or model organism-based. High
throughput screens for targets that address unmet needs in
Obesogenic Behaviors and Weight Outcomes cancer prevention, treatment or diagnosis are encouraged.
(R03) This FOA utilizes the NIH R21 Exploratory/Developmental
PA-10-054 Research Grant mechanism.
Deadline: October 16, 2012 Period of Support Up to 2 years
"http://grants.nih.gov/grants/guide/pa-files/PA-10-054.html" Funds/Direct Costs $275,000 direct costs for entire
About period of support, up to $200,000
This Funding Opportunity Announcement (FOA) direct costs allowed in any single year
encourages applications that propose to: (1) foster Program Contact Suzanne Forry-Schaudies, PhD
multidisciplinary research that will evaluate how policies (301) 435-9147
(federal, state and school district levels) can influence forryscs@mail.nih.gov
school physical activity and nutrition environments, youths’
obesogenic behaviors (e.g., nutrition and physical activity
behaviors), and weight outcomes; (2) understand how
schools are implementing these policies and examine multi-
level influences on adoption and implementation at various
levels (e.g. federal, state, school district, and school); and
(3) understand the synergistic or counteractive effect of
school nutrition and physical activity polices on the home
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 27 of 45
Multiple Institutes, including the National Cancer Institutes and Centers may be proposed. This FOA utilizes
Institute the NIH Small Grant Program (R03) mechanism.
Biomechanisms of Peripheral Nerve Damage by Period of Support Up to 2 years
Anti-Cancer Therapy (R21) Funds/Direct Costs $50,000 direct costs per year
PA-12-083 Program Contact Rebecca Liddell Huppi PhD
Deadline: October 16, 2012 31 Center Drive, Suite 3A33
"http://grants.nih.gov/grants/guide/pa-files/PA-12-083.html" Bethesda, MD 20892-2440
(301) 496-4995
About
liddellr@exchange.nih.gov
The purpose of this Funding Opportunity Announcement
(FOA) is to encourage basic biologic research on damage to
the peripheral nervous system instigated by pharmacologic Multiple Institutes, including the National Cancer
cancer treatments, known as chemotherapy-induced Institute
peripheral neuropathy (CIPN). This FOA intends to Research on the Health of LGBTI Populations
stimulate neuroscience researchers to apply their expertise
(R21)
from studying neuropathies focused on diabetic and
inherited diseases to the injuries incurred by cancer PA-12-113
treatments. More data is necessary to understand the Deadline: October 16, 2012
mechanisms of neuronal damage and to identify the targets "http://grants.nih.gov/grants/guide/pa-files/PA-12-113.html"
instrumental to CIPN initiation and maintenance. Preclinical
research that focuses not only on peripheral neuropathic About
pain but also on neurosensory symptoms such as The National Institutes of Health (NIH) is committed to
paresthesias and peripheral anesthesias is invited. The supporting research that will increase scientific
ultimate goal of this FOA is to lead to a molecular understanding of the health status of various population
understanding of CIPN that allows for the rational groups and improve the effectiveness of health interventions
development of interventions that will treat or prevent CIPN. and services for individuals within those groups. High
This FOA utilizes the NIH Exploratory/Developmental (R21) priority is placed on research on populations that appear to
Research Grant Award mechanism. have distinctive health risk profiles but have received
insufficient attention from investigators. This Funding
Period of Support Up to 2 years Opportunity Announcement (FOA) highlights a particular
Funds/Direct Costs $275,000 direct costs for entire community: lesbian, gay, bisexual, transgender, intersex,
period of support, up to $200,000 and related populations (designated here as LGBTI
direct costs allowed in any single year populations). Basic, social, behavioral, clinical, and services
Program Contact Joanna M. Brell, MD research relevant to the missions of the sponsoring
6130 Executive Boulevard, Room 2014 Institutes and Centers may be proposed. This FOA utilizes
Bethesda, MD 20892-7340 the NIH Exploratory/Developmental Research Grant Award
mechanism.
(301) 496-8541
brelljm@mail.nih.gov Period of Support Up to 2 years
Funds/Direct Costs $275,000 direct costs for entire
period of support, up to $200,000
Multiple Institutes, including the National Cancer
direct costs allowed in any single year
Institute
Program Contact Rebecca Liddell Huppi PhD
Research on the Health of LGBTI Populations 31 Center Drive, Suite 3A33
(R03) Bethesda, MD 20892-2440
PA-12-112 (301) 496-4995
Deadline: October 16, 2012 liddellr@exchange.nih.gov
"http://grants.nih.gov/grants/guide/pa-files/PA-12-112.html"
About National Cancer Institute
The National Institutes of Health (NIH) is committed to NCI Small Grants Program for Cancer Research
supporting research that will increase scientific (NCI Omnibus R03)
understanding of the health status of various population
groups and improve the effectiveness of health interventions PAR-12-144
and services for individuals within those groups. High Deadline: October 16, 2012
priority is placed on research on populations that appear to "http://grants.nih.gov/grants/guide/pa-files/PAR-12-144.html"
have distinctive health risk profiles but have received
About
insufficient attention from investigators. This Funding
Opportunity Announcement (FOA) highlights a particular This Funding Opportunity Announcement (FOA) supports
community: lesbian, gay, bisexual, transgender, intersex, small research projects on cancer that can be carried out in
and related populations (designated here as LGBTI a short period of time with limited resources. The R03 grant
populations). Basic, social, behavioral, clinical, and services mechanism supports different types of projects including
research relevant to the missions of the sponsoring pilot and feasibility studies; secondary analysis of existing
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 28 of 45
data; small, self-contained research projects; development Exploratory/Developmental Grant (R21) mechanism.
of research methodology; and development of new research
Period of Support Up to 2 years
technology.
Funds/Direct Costs $275,000 direct costs over entire
Period of Support Up to 2 years period of support, no more than
Funds/Direct Costs $50,000 direct costs per year $200,000 may be requested in any
Program Contact Referral Officer single year.
6116 Executive Boulevard, Room 8041 Program Contact Dr. Rebecca Liddell Huppi
Bethesda, MD 20892-8329 31 Center Drive, Building 31, Room
(301) 496-3428 3A33
ncirefof@dea.nci.nih.gov Bethesda, MD 20892-2440
(301) 496-4995
National Cancer Institute liddellr@mail.nih.gov
NCI Exploratory/Developmental Research Grant
Multiple Institutes, including the National Cancer
Program (NCI Omnibus R21)
Institute
PAR-12-145
School Nutrition and Physical Activity Policies,
Deadline: October 16, 2012
Obesogenic Behaviors and Weight Outcomes
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-145.html"
(R21)
About
PA-10-053
This Funding Opportunity Announcement (FOA) supports
the development of new research activities in all areas of Deadline: October 16, 2012
cancer research. These studies may involve considerable "http://grants.nih.gov/grants/guide/pa-files/PA-10-053.html"
risk but may lead to a breakthrough in a particular area, or About
to the development of novel techniques, agents, This Funding Opportunity Announcement (FOA)
methodologies, models, or applications that could have a encourages applications that propose to: (1) foster
major impact on a field of cancer research (biomedical, multidisciplinary research that will evaluate how policies
behavioral, or clinical). This FOA utilizes the NIH (federal, state and school district levels) can influence
Exploratory/Developmental Grant (R21) mechanism. school physical activity and nutrition environments, youths’
Period of Support Up to 2 years obesogenic behaviors (e.g., nutrition and physical activity
Funds/Direct Costs $275,000 direct costs for entire behaviors), and weight outcomes; (2) understand how
period of support, up to $200,000 schools are implementing these policies and examine multi-
direct costs in any single year level influences on adoption and implementation at various
Program Contact Referral Officer levels (e.g. federal, state, school district, and school); and
(3) understand the synergistic or counteractive effect of
6116 Executive Boulevard, Room 8041 school nutrition and physical activity polices on the home
Bethesda, MD 20892-8329 and community environment and body weight. The R21
(301) 496-3428 grant mechanism is intended to encourage
ncirefof@dea.nci.nih.gov exploratory/developmental research by providing support for
the early and conceptual stages of project development.
Multiple Institutes, including the National Cancer Period of Support Up to 2 years
Institute Funds/Direct Costs $275,000 direct costs over an R21
Basic Research on HIV Persistence (R21) two-year period, with up to $200,000
in direct costs allowed in any single
PA-12-162 year
Deadline: October 16, 2012 Program Contact Tanya Agurs-Collins, PhD, RD
"http://grants.nih.gov/grants/guide/pa-files/PA-12-162.html" 6130 Executive Blvd., Room 4084
About Bethesda, MD 20892-7324
The purpose of this Funding Opportunity Announcement (301) 594-6637
(FOA) is to increase our understanding of persistent HIV-1 collinsta@mail.nih.gov
infection in patients under highly active anti-retroviral
therapy (HAART). Support would be through soliciting
applications for hypothesis-driven basic research in Multiple Institutes, including the National Cancer
HIV/AIDS that is focused on directly achieving this aim. The Institute
emphasis of this initiative is on the development of new Mentored Patient-Oriented Research Career
ideas and approaches in HIV-1 persistence including model Development Award (K23)
and assay development that may directly inform future
studies on the design of therapeutic strategies to achieve
PA-11-194
long term remission without treatment or a complete Deadline: October 12, 2012
eradication of residual virus and complete cure for HIV "http://grants.nih.gov/grants/guide/pa-files/PA-11-194.html"
infection and AIDS. This FOA utilizes the
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 29 of 45
About Period of Support Up to 2 years
The purpose of the NIH Mentored Patient-Oriented Funds/Direct Costs $50,000 direct costs per year
Research Career Development Award (K23) is to support Program Contact Gina Tesauro, MSW
the career development of investigators who have made a
commitment to focus their research endeavors on patient- 6130 Executive Boulevard
oriented research. Clinically trained professionals or Rockville, MD 20852
individuals with a clinical degree who are interested in (301) 435-2836
further career development in biomedical research that is gina.tesauro@nih.gov
not patient-oriented should refer to the Mentored Clinical
Scientist Career Development (Parent K08) Award.
Multiple Institutes, including the National Cancer
Period of Support Up to 5 years Institute
Funds/Direct Costs Salary Support: Up to $100,000 plus Biomechanisms of Peripheral Nerve Damage by
fringe benefits per year. Research
Support: Up to $30,000 per year.
Anti-Cancer Therapy (R01)
Program Contact Susan E. Lim, PhD PA-12-082
6116 Executive Boulevard, Room 7043 Deadline: October 5, 2012
Rockville, MD 20852 "http://grants.nih.gov/grants/guide/pa-files/PA-12-082.html"
(301) 496-8580 About
lims@mail.nih.gov The purpose of this Funding Opportunity Announcement
(FOA) is to encourage basic biologic research on damage to
the peripheral nervous system instigated by pharmacologic
National Cancer Institute
cancer treatments, known as chemotherapy-induced
Small Grants for Behavioral Research in Cancer peripheral neuropathy (CIPN). This FOA intends to
Control (R03) stimulate neuroscience researchers to apply their expertise
PAR-12-035 from studying neuropathies focused on diabetic and
inherited diseases to the injuries incurred by cancer
Deadline: October 18, 2012
treatments. More data is necessary to understand the
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-035.html" mechanisms of neuronal damage and to identify the targets
About instrumental to CIPN initiation and maintenance. Preclinical
This Funding Opportunity Announcement (FOA) invites research that focuses not only on peripheral neuropathic
applications for research projects that can be carried out in pain but also on neurosensory symptoms such as
a short period of time with limited resources in behavioral paresthesias and peripheral anesthesias is invited. The
research in cancer prevention and control. This FOA is ultimate goal of this FOA is to lead to a molecular
designed to enhance basic and applied behavioral sciences understanding of CIPN that allows for the rational
research in the context of cancer control, with a secondary development of interventions that will treat or prevent CIPN.
goal of attracting new investigators to the field from a variety This FOA utilizes the NIH Research Project Grant (R01)
of biomedical, behavioral and public health disciplines. grant mechanism.
Proposed research projects would include pilot or feasibility Period of Support Up to 5 years
studies, secondary analyses of existing data, and meta- Funds/Direct Costs Application budgets are not limited,
analyses particularly in the areas of: (1) basic biobehavioral but need to reflect actual needs of
and psychological services, (2) behavioral genetics, (3) the proposed project.
cancer survivorship and bereavement, (4) health behaviors,
(5) health communication and informatics, (6) health Program Contact Joanna M. Brell, MD
disparities, (7) processes of cancer care including delivery 6130 Executive Boulevard, Room 2014
and utilization, and (8) tobacco control. To be appropriate Bethesda, MD 20892-7340
for this FOA, proposed research must be significantly (301) 496-8541
applicable to cancer control research and address specific brelljm@mail.nih.gov
gaps in knowledge or methodologies. Although the specific
study proposed may attempt only to obtain preliminary data
and/or conduct pilot studies in support of a future, more Multiple Institutes, including the National Cancer
detailed study, it is important that a long-term human cancer Institute
control hypothesis and supporting scientific justification be Research on the Health of LGBTI Populations
presented. Investigators new to the field of behavioral (R01)
cancer control research, including early-stage and
established investigators looking to refocus or apply their
PA-12-111
expertise to cancer control, are encouraged to apply for this Deadline: October 5, 2012
small grants announcement. This FOA utilizes the NIH "http://grants.nih.gov/grants/guide/pa-files/PA-12-111.html"
Small Grant (R03) mechanism.
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 30 of 45
About Multiple Institutes, including the National Cancer
The National Institutes of Health (NIH) is committed to Institute
supporting research that will increase scientific
understanding of the health status of various population
Biology of Manual Therapies (R01)
groups and improve the effectiveness of health interventions PA-10-209
and services for individuals within those groups. High Deadline: October 5, 2012
priority is placed on research on populations that appear to "http://grants.nih.gov/grants/guide/pa-files/PA-10-209.html"
have distinctive health risk profiles but have received
insufficient attention from investigators. This Funding About
Opportunity Announcement (FOA) highlights a particular This Funding Opportunity Announcement (FOA)
community: lesbian, gay, bisexual, transgender, intersex, encourages grant applications that propose to investigate
and related populations (designated here as LGBTI the basic science and mechanisms of action underlying the
populations). Basic, social, behavioral, clinical, and services biomechanical, immunological, endocrinological and/or
research relevant to the missions of the sponsoring neurophysiological consequences of manual therapies,
Institutes and Centers may be proposed. This FOA utilizes such as spinal manipulation, mobilization and massage
the NIH Research Project Grant (R01) grant mechanism. therapy. Such studies will both provide information on the
possible mechanisms of action of manual therapies, and
Period of Support Up to 5 years also provide a stronger foundation for ongoing and planned
Funds/Direct Costs Application budgets are not limited, clinical studies. Applicants are encouraged to employ
but need to reflect actual needs of cutting-edge technologies to broaden or strengthen the
the proposed project. knowledge bases needed to improve clinical practice. This
Program Contact Rebecca Liddell Huppi, PhD FOA utilizes the R01 research grant mechanism.
31 Center Drive, Suite 3A33 Period of Support Up to 5 years
Bethesda, MD 20892-2440 Funds/Direct Costs Not specified
(301) 496-4995 Program Contact Isis S. Mikahil, MD, MPH, DrPH
liddellr@exchange.nih.gov 6116 Executive Boulevard, Room 609
Rockville, MD 20892-8339
Multiple Institutes, including the National Cancer (301) 496-8159
Institute mikhaili@mail.nih.gov
Basic Research on HIV Persistence (R01)
PA-12-161 National Cancer Institute
Deadline: October 5, 2012 NCI Mentored Research Scientist Development
"http://grants.nih.gov/grants/guide/pa-files/PA-12-161.html" Award to Promote Diversity (K01)
About PAR-12-050
The purpose of this Funding Opportunity Announcement Deadline: October 12, 2012
(FOA) is to increase our understanding of persistent HIV-1 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-050.html"
infection in patients under highly active anti-retroviral
therapy (HAART). Support would be through soliciting About
applications for hypothesis-driven basic research in The purpose of this award is to provide support and
HIV/AIDS that is focused on directly achieving this aim. The “protected time” (three, four, or five years) for an intensive,
emphasis of this initiative is on the development of new supervised career development experience in the
ideas and approaches in HIV-1 persistence including model biomedical, behavioral, or clinical sciences leading to
and assay development that may directly inform future research independence. Awards are not renewable and they
studies on the design of therapeutic strategies to achieve are not transferable from one principal investigator (PI) to
long term remission without treatment or a complete another. Applications are invited from individuals
eradication of residual virus and complete cure for HIV representative of groups that have been shown to be
infection and AIDS. This FOA utilizes the NIH Research underrepresented in health-related science, who have been
Project Grant (R01) mechanism. recipients of an NIH Research Supplement to Promote
Diversity Award, any Ruth L. Kirschstein National Research
Period of Support Up to 5 years Service Award (individual F31/F32 or institutional T32), or
Funds/Direct Costs Application budgets are not limited, can demonstrate that they have been supported in a
but need to reflect actual needs of mentored capacity within any research grant equivalent to
the proposed project. an NIH peer-reviewed research grant (e.g., American
Program Contact Dr. Rebecca Liddell Huppi Cancer Society [ACS] research grant). The overarching goal
31 Center Drive, Building 31, Room of this Funding Opportunity Announcement (FOA) is to
3A33 diversify and expand the pool of independent and talented
Bethesda, MD 20892-2440 cancer research investigators. This FOA utilizes the NIH
Mentored Research Scientist Development Award (K01)
(301) 496-4995
mechanism.
liddellr@mail.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 31 of 45
Period of Support Up to 5 years clinical, behavioral, and social sciences. The NCI
Funds/Direct Costs Up to $100,000 per year toward recognizes a unique and compelling need to promote
salary, $30,000 per year toward diversity in the patient-oriented research workforce.
research development costs Period of Support Up to 5 years
Budgetary Notes 8% indirect costs are allowed Funds/Direct Costs Up to $100,000 per year for salary,
Program Contact John O. Ojeifo, MD, PhD, MBA up to $30,000 per year in research
6116 Executive Boulevard, Suite 602 development costs
Rockville, MD 20852 Program Contact John O. Ojeifo, MD, PhD, MBA
(301) 496-8589 6116 Executive Boulevard, Suite 602
ojeifojo@mail.nih.gov Rockville, MD 20852
(301) 496-8589
National Cancer Institute ojeifojo@mail.nih.gov
NCI Mentored Clinical Scientist Research Career
Development Award to Promote Diversity (K08) National Cancer Institute
PAR-12-051 NCI Transition Career Development Award to
Deadline: October 12, 2012 Promote Diversity (K22)
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-051.html" PAR-12-062
Deadline: October 12, 2012
About
The primary purpose of this program is to prepare "http://grants.nih.gov/grants/guide/pa-files/PAR-12-062.html"
individuals for careers that have a significant impact on the About
health-related research needs of the nation. This program The purpose of this award is to help ensure that a diverse
represents the continuation of a long-standing NIH program pool of highly trained scientists are available in adequate
that provides support and protected time to individuals with numbers and in appropriate research areas to address the
a clinical doctoral degree for an intensive, supervised nation's biomedical, behavioral, and clinical research needs.
research career development experience in the fields of Applications are invited from recipients of the NCI Mentored
biomedical and behavioral research, including translational Career Development Award to Promote Diversity, or from
research. This NCI-sponsored K08 award is specifically advanced postdoctoral and/or newly independent research
designed to promote career development of clinical scientists representative of groups that are
scientists from diverse backgrounds that have been shown underrepresented in biomedical, behavioral, clinical, and/or
to be underrepresented in health-related science and for social sciences. This award will provide "protected time" for
those who are committed to a career in basic biomedical, recipients to develop and receive support for their initial
behavioral or translational cancer research, including cancer research program.
research on cancer health disparities.
Period of Support Up to 3 years
Period of Support Up to 5 years Funds/Direct Costs $100,000 per year toward salary,
Funds/Direct Costs Up to $100,000 per year toward $50,000 per year for research
salary plus benefits and up to development costs
$30,000 toward research Program Contact Anil Wali, PhD
development costs
6116 Executive Boulevard, Suite 602
Program Contact John O. Ojeifo, MD, PhD, MBA
Rockville, MD 20852
6116 Executive Boulevard, Suite 602
(301) 496-8589
Rockville, MD 20892
walia@mail.nih.gov
(301) 496-8589
ojeifojo@mail.nih.gov
Multiple Institutes, including the National Cancer
Institute
National Cancer Institute
NIH Pathway to Independence Award (K99/R00)
NCI Mentored Patient-Oriented Research Career
PA-11-197
Development Award to Promote Diversity (K23)
Deadline: October 12, 2012
PAR-12-052
"http://grants.nih.gov/grants/guide/pa-files/PA-11-197.html"
Deadline: October 12, 2012
About
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-052.html"
The primary purpose of the Pathway to Independence
About Award (K99/R00) program is to increase and maintain a
The purpose of this award is to support the career strong cohort of new and talented NIH-supported
development of investigators who have made a commitment independent investigators. The program is designed to
to focus their research endeavors on patient-oriented facilitate a timely transition from a mentored postdoctoral
cancer research (POR). The award supports individuals with research position to a stable independent research position
a health professional doctoral degree from groups currently with independent NIH or other independent research
underrepresented on a national level in the biomedical, support at an earlier stage than is currently the norm.
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 32 of 45
Period of Support Up to 5 years Period of Support Up to 5 years
Funds/Direct Costs Initial mentored phase (K99) up to Funds/Direct Costs $100,000 per year for salary,
$90,000 per year; independent $30,000 per year for research
investigator phase (R00) up to development costs
$249,000 per year Program Contact Susan Perkins, PhD
Program Contact Nancy C. Lohrey 6116 Executive Boulevard, Suite 700
6116 Executive Blvd., Suite 7027 Bethesda, MD 20892-8346
Bethesda, MD 20892 (301) 496-8580
(301) 496-8580 perkinsu@mail.nih.gov
lohreyn@mail.nih.gov
National Cancer Institute
Multiple Institutes, including the National Cancer Mitochondria in Cancer Epidemiology, Detection,
Institute Diagnosis and Prognosis (R21)
Mentored Quantitative Research Development PA-11-074
Award (K25) Deadline: October 16, 2012
PA-11-196 "http://grants.nih.gov/grants/guide/pa-files/PA-11-074.html"
Deadline: October 12, 2012
About
"http://grants.nih.gov/grants/guide/pa-files/PA-11-196.html" This Funding Opportunity Announcement (FOA)
About encourages applications that propose to develop and
The purpose of the Mentored Quantitative Research Career validate new mitochondrial-related biomarkers for cancer
Development Award (K25) is to attract to NIH-relevant early detection, diagnosis, prognosis, risk assessment, and
research those investigators whose quantitative science and response to preventive and ameliorative treatments. Using
engineering research has thus far not been focused the NIH Exploratory/Developmental Grant (R21) funding
primarily on questions of health and disease. The K25 mechanism, this FOA focuses on early and conceptual
award will provide support and “protected time” for a period stages of research projects.
of supervised study and research for productive Period of Support Up to 2 years
professionals with quantitative (e.g., mathematics, statistics, Funds/Direct Costs $275,000 over an R21 two-year
economics, computer science, imaging science, informatics, period, up to $200,000 in direct costs
physics, chemistry) and engineering backgrounds to allowed in any single year
integrate their expertise with NIH-relevant research.
Program Contact Mukesh Verma, PhD
Period of Support Up to 5 years 6130 Executive Blvd., Room 5100
Funds/Direct Costs Salary Support: Up to $100,000 plus Bethesda, MD 20892-7324
fringe benefits per year. Research
Support: Up to $40,000 per year. (301) 594-7344
vermam@mail.nih.gov
Program Contact Sonia Jakowlew, PhD
6116 Executive Boulevard, Suite 700
Bethesda, MD 20892
National Cancer Institute
(301) 496-8580 NCI Transition Career Development Award (K22)
jakowles@mail.nih.gov PAR-12-121
Deadline: October 12, 2012
National Cancer Institute "http://grants.nih.gov/grants/guide/pa-files/par-12-121.html"
Cancer Prevention, Control, Behavioral and About
Population Sciences Career Development Award This Funding Opportunity Announcement (FOA) represents
(K07) the continuation of an NCI program to facilitate the transition
of investigators in mentored, non-independent cancer
PAR-12-067 research positions to independent faculty cancer research
Deadline: October 12, 2012 positions. This goal is achieved by providing protected time
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-067.html" through salary and research support for the initial 3 years of
About the first independent tenure-track faculty position, or its
equivalent. This FOA utilizes the NIH K22 Career
The purpose of the Cancer Prevention, Control, Behavioral
Development Award mechanism.
Sciences, and Population Sciences Career Development
Award is to support the career development of junior
investigators with research or health professional doctoral
degrees who want to become cancer-focused academic
researchers in cancer prevention, cancer control, or the
behavioral or population sciences. This Funding Opportunity
Announcement (FOA) utilizes the NIH Academic Career
Award (K07) mechanism.
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 33 of 45
Period of Support Up to 3 years Multiple Institutes, including the National Cancer
Funds/Direct Costs $100,000 per year salary plus fringe Institute
benefits, $50,000 in direct costs per Midcareer Investigator Award in Patient-Oriented
year for research and development
expenses Research (K24)
Program Contact Sonia Jakowlew, PhD PA-11-195
6116 Executive Boulevard, Suite 700 Deadline: October 12, 2012
Bethesda, MD 20892-8346 "http://grants.nih.gov/grants/guide/pa-files/PA-11-195.html"
(301) 496-8580 About
jakowles@mail.nih.gov The purpose of the NIH Midcareer Investigator Award in
Patient-Oriented Research (K24) is to provide support to
mid-career health-professional doctorates or equivalent who
Multiple Institutes, including the National Cancer are typically at the Associate Professor level or the
Institute equivalent for protected time to devote to patient-oriented
Solicitation of Assays for High Throughput research (POR) and to act as research mentors primarily for
Screening (HTS) to Discover Chemical Probes clinical residents, clinical fellows and/or junior clinical faculty.
(R01) Period of Support Up to 5 years
PAR-12-058 Funds/Direct Costs Salary Support: Up to maximum
Deadline: October 5, 2012 salary cap: $199,700 (FY 2011) plus
fringe benefits per year, for 25-50%
"http://grants1.nih.gov/grants/guide/pa-files/PAR-12-
effort. Research Support: Up to
058.html"
$50,000 per year.
About Program Contact Susan E. Lim, PhD
This Funding Opportunity Announcement (FOA) 6116 Executive Boulevard, Room 7043
encourages investigators to form collaborations with an
Rockville, MD 20852
established academic, nonprofit, or commercial high
throughput screening (HTS) facility that has the requisite (301) 496-8580
expertise and experience to implement HTS-ready assays lims@mail.nih.gov
for the discovery and development of small molecule
chemical probes. Through this FOA, the NCI is interested in Multiple Institutes, including the National Cancer
high throughput screens intended to identify small Institute
molecules for use in elucidating molecular, cellular, or in
vivo mechanisms or processes of probable or known Translational Scholar Career Awards in
importance to cancer biology, and for use in developing Pharmacogenomics and Personalized Medicine
strategies for cancer prevention, diagnosis, treatment or (K23)
clinical monitoring of treatment. Screens may be PA-11-009
biochemical, cellular or model organism-based. High
Deadline: October 12, 2012
throughput screens for targets that address unmet needs in
cancer prevention, treatment or diagnosis are encouraged. "http://grants.nih.gov/grants/guide/pa-files/PA-11-009.html"
This FOA utilizes the NIH R01 Research Project Grant About
mechanism. The purpose of this Mentored Patient-Oriented Research
Period of Support Up to 3 years Career Development Award (K23) is to provide salary and
Funds/Direct Costs The number of awards is contingent “protected time” (up to five years for this award) to support
upon NIH appropriations, and the the career development of investigators who have made a
submission of a sufficient number of commitment to focus their research endeavors on patient-
meritorious applications oriented research. Each Research Career Development
Award must be tailored to meet the individual needs of the
Budgetary Notes Applicants need to reflect the actual
candidate. The Translational Scholar Awards in
needs of the proposed costs associated
Pharmacogenomics and Personalized Medicine program is
with HTS and post-HTS follow-up assays
intended to address the scarcity of investigators cross-
Program Contact Suzanne Forry-Schaudies, PhD trained in both clinical research core competencies and
(301) 435-9147 modern methods required to address pharmacogenomics
forryscs@mail.nih.gov research problems in patient populations. Dual mentors
from the Clinical and Translational Science Awards
consortium and the Pharmacogenomics Research Network
are required. This FOA utilizes the NIH Research Career
Development Award K23 award mechanism.
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 34 of 45
Period of Support Up to 3 years About
Funds/Direct Costs $200,000 per year This Funding Opportunity Announcement (FOA)
Program Contact Susan Lim, PhD encourages the submission of applications that propose to
promote innovative research across multiple disciplines for
6116 Executive Boulevard, Rm. 7043 a better understanding of the biology, etiology, detection,
Bethesda, MD 20892-8346 prevention, and treatment of pancreatic cancer. This FOA
(301) 496-8580 focuses on pilot projects in early and conceptual stages that
lims@mail.nih.gov could provide a basis for more extended research. These
studies may involve considerable risk but should have the
potential to generate highly innovative findings or
Multiple Institutes, including the National Cancer
technical/methodological improvements that could have a
Institute major impact on the field of pancreatic cancer research.
Mentored Clinical Scientist Research Career This FOA utilizes the R21 Exploratory/Developmental
Development Award (K08) Research Grant Award mechanism.
PA-11-193 Period of Support Up to 2 years
Deadline: October 12, 2012 Funds/Direct Costs $275,000 direct costs for entire
"http://grants.nih.gov/grants/guide/pa-files/PA-11-193.html" period of support, up to $200,000 in
direct costs allowed in any single year
About
Program Contact Mukesh Verma, PhD
The primary purpose of the NIH Mentored Clinical Scientist
Research Career Development Awards (K08) program is to 6130 Executive Boulevard, Room 5140
prepare qualified individuals for careers that have a Bethesda, MD 20892-7328
significant impact on the health-related research needs of (301) 594-7344
the nation. This program represents the continuation of a vermam@mail.nih.gov
long-standing NIH program that provides support and
“protected time” to individuals with a clinical doctoral degree
Multiple Institutes, including the National Cancer
for an intensive, supervised research career development
experience in the fields of biomedical and behavioral Institute
research, including translational research. Individuals with a Research on Ethical Issues in Biomedical, Social,
clinical doctoral degree interested in pursuing a career in and Behavioral Research (R03)
patient-oriented research should refer to the NIH Mentored PA-11-181
Patient-Oriented Research Career Development Award
(Parent K23). Prospective candidates are encouraged to Deadline: October 16, 2012
contact the relevant NIH staff for IC-specific programmatic "http://grants.nih.gov/grants/guide/pa-files/PA-11-181.html"
and budgetary information. Former PD/PIs on NIH research About
project (R01), program project (P01), center grants, FIRST The purpose of this Funding Opportunity Announcement
Awards (R29), sub-projects of program project (P01) or (FOA) is to support applications that propose to study high
center grants, other career development awards priority bioethical challenges and issues associated with the
(K–awards), or the equivalent are not eligible. Former types of biomedical, social and behavioral research
principal investigators of an NIH Small Grant (R03), supported by the participating NIH Institutes/Centers. The
Exploratory/Developmental Grant (R21), Dissertation following specific bioethics topics will be given the highest
Awards (R36), or SBIR/STTR (R41, R42, R43, R44) remain priority for consideration. These are organized into seven
eligible. categories: 1) ethical considerations of new and emerging
Period of Support Up to 5 years technologies; 2) research study design issues; 3) issues
Funds/Direct Costs Salary Support: Up to $100,000 plus associated with therapeutic misconception and the interface
fringe benefits per year. Research between treatment and research; 4) research involving
Support: Up to $30,000 per year vulnerable populations and urgent situations; 5) research
Program Contact Dorkina Myrick, MD, PhD with existing specimens, data, and health information; 6)
dissemination and translation of research findings; and 7)
6116 Executive Boulevard, Suite 7033 oversight of research. This FOA will utilize the R03 Small
Bethesda, MD 20892-8346 Grant Program mechanism.
(301) 496-8580
Period of Support Up to 2 years
myrickd@mail.nih.gov
Funds/Direct Costs $50,000 direct costs per year
Program Contact Kim Witherspoon
National Cancer Institute
(301) 496-8866
Pilot Studies in Pancreatic Cancer (R21) kw265c@nih.gov
PA-11-297
Deadline: October 16, 2012
"http://grants1.nih.gov/grants/guide/pa-files/PA-11-297.html"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 35 of 45
Multiple Institutes, including the National Cancer Period of Support Up to 2 years
Institute Funds/Direct Costs $275,000 direct costs for entire
Research on Ethical Issues in Biomedical, Social, period of support, up to $200,000
direct costs allowed in any single year
and Behavioral Research (R21)
Program Contact Young S. Kim, PhD
PA-11-182
6130 Executive Boulevard, Room 3156
Deadline: October 16, 2012
Bethesda, MD 20892-7328
"http://grants.nih.gov/grants/guide/pa-files/PA-11-182.html"
(301) 496-0126
About yk47s@nih.gov
The purpose of this Funding Opportunity Announcement
(FOA) is to support applications that propose to study high
priority bioethical challenges and issues associated with the
Multiple Institutes, including the National Cancer
types of biomedical, social, and behavioral research Institute
supported by the participating NIH Institutes/Centers. The Mechanisms of Alcohol-Associated Cancers (R21)
following specific bioethics topics will be given the highest PA-12-147
priority for consideration. These are organized into seven
categories: 1) ethical considerations of new and emerging Deadline: October 16, 2012
technologies; 2) research study design issues; 3) issues "http://grants.nih.gov/grants/guide/pa-files/PA-12-147.html"
associated with therapeutic misconception and the interface About
between treatment and research; 4) research involving This Funding Opportunity Announcement invites
vulnerable populations and urgent situations; 5) research applications from researchers with broad ranges of
with existing specimens, data, and health information; 6) expertise to study the mechanisms by which alcohol
dissemination and translation of research findings; and 7) increases cancer risk. Target sites for alcohol-related
oversight of research. This FOA utilizes the R21 carcinogenesis include the oral cavity, pharynx, esophagus,
Exploratory/Developmental Research Grant Award larynx, breast, liver, and colon. A better understanding of the
mechanism. molecular basis by which alcohol increases cancer risk
Period of Support Up to 2 years could lead to improved therapeutic approaches and
Funds/Direct Costs $275,000 direct costs for entire preventative strategies and would provide guidance on safe
period of support, up to $200,000 levels of alcohol consumption. The goal of this program
direct costs allowed in any single year announcement is to stimulate a broad range of research into
the mechanisms by which alcohol contributes to
Program Contact Kim Witherspoon
carcinogenesis. This FOA utilizes the NIH Research Project
(301) 496-8866 Grant (R01) award mechanism.
kw265c@nih.gov
Period of Support Up to 2 years
Funds/Direct Costs $275,000 direct costs for the entire
National Cancer Institute period of support, up to $200,000
Exploratory Cancer Prevention Studies Involving direct costs in any single year
Molecular Targets for Bioactive Food Components Program Contact Alice C. Wong, CRA
(R21) 6120 Executive Boulevard, Suite 243P
PA-10-088 Rockville, MD 20852
Deadline: October 16, 2012 (301) 496-9312
"http://grants1.nih.gov/grants/guide/pa-files/PA-10-088.html" wongalice@mail.nih.gov
About
This Funding Opportunity Announcement (FOA) Multiple Institutes, including the National Cancer
encourages exploratory research on the role of nutrition in Institute
cancer prevention. Specifically, this FOA seeks to promote Nanoscience and Nanotechnology in Biology and
cancer prevention research to identify and characterize Medicine (R21)
molecular targets for bioactive food components. For the
purpose of this FOA, a bioactive food component is defined PA-11-149
as a dietary constituent that has a health benefit by altering Deadline: October 16, 2012
one or more cellular processes when provided in quantities "http://grants.nih.gov/grants/guide/pa-files/PA-11-149.html"
over and beyond that needed for basic nutrition. This FOA
About
utilizes the NIH Exploratory/Developmental (R21) grant
mechanism. This initiative encourages applications that apply
nanoscience and nanotechnology approaches to address
problems in biology and medicine. The purpose of this
Funding Opportunity Announcement (FOA) is to provide
support for cutting-edge nanoscience and nanotechnology
research that can lead to biomedical breakthroughs and
new investigations into the diagnosis, treatment and
management of an array of diseases and traumatic injuries.
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 36 of 45
Nanoscience and nanotechnology have the capacity to drive National Cancer Institute
a new wave of medical innovation through the engineering
The Effect of Racial and Ethnic
of bioactive nanoscale structures, processes and systems
based on the advancement of our understanding of biology Discrimination/Bias on Health Care Delivery (R03)
at the nanoscale. Therefore, this FOA will also support PA-11-164
research projects that develop new or improved Deadline: October 16, 2012
nanotechnology and nanoscience-based tools, methods, "http://grants.nih.gov/grants/guide/pa-files/PA-11-164.html"
concepts, and devices that lead to a better understanding of
basic biology in addition to conducting translational About
biomedical studies. Applications that focus on novel or This Funding Opportunity Announcement (FOA)
exploratory approaches that are risky but have potentially a encourages the submission of applications that propose to:
high impact are encouraged as well as proposed discovery (1) improve the measurement of racial/ethnic discrimination
research that may lead to new areas of biomedical in health care delivery systems through improved
investigations. This FOA utilizes the NIH instrumentation, data collection, and statistical/analytical
Exploratory/Developmental Research Grant Award (R21) techniques; (2) to enhance understanding of the influence of
mechanism. racial/ethnic discrimination in health care delivery and its
association with disparities in disease incidence, treatment,
Period of Support Up to 2 years and outcomes among disadvantaged racial/ethnic minority
Funds/Direct Costs $275,000 direct costs for entire groups: and (3) to reduce the prevalence of racial/ethnic
period of support, up to $200,000 health disparities through the development of interventions
direct costs allowed in any single year to reduce the influence of racial/ethnic discrimination on
Program Contact Piotr Grodzinski health care delivery systems in the United States (U.S.).
(301) 594-4177 This grant mechanism supports pilot or feasibility studies
grodzinp@mail.nih.gov and developmental research projects with the intention of
obtaining sufficient preliminary data for a subsequent
Investigator-initiated Research Project Grant (R01)
Multiple Institutes, including the National Cancer application. This FOA will utilize the NIH Small Grant (R03)
Institute mechanism.
The Effect of Racial and Ethnic Period of Support Up to 2 years
Discrimination/Bias on Health Care Delivery (R21) Funds/Direct Costs $50,000 per year
PA-11-163 Program Contact Vickie L. Shavers, PhD
Deadline: October 16, 2012 6130 Executive Blvd., Room 4005
"http://grants.nih.gov/grants/guide/pa-files/PA-11-163.html" Bethesda, MD 20892-7344
About (301) 594-1725
This Funding Opportunity Announcement (FOA) shaversv@mail.nih.gov
encourages the submission of research project grant
applications from institutions/organizations that propose to: National Cancer Institute
(1) improve the measurement of racial/ethnic discrimination
in health care delivery systems through improved NCI Established Investigator Award in Cancer
instrumentation, data collection, and statistical/analytical Prevention and Control (K05)
techniques; (2) to enhance understanding of the influence of PAR-12-065
racial/ethnic discrimination in health care delivery and its Deadline: October 12, 2012
association with disparities in disease incidence, treatment,
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-065.html"
and outcomes among disadvantaged racial/ethnic minority
groups: and (3) to reduce the prevalence of racial/ethnic About
health disparities through the development of interventions The purpose of the NCI Established Investigator Award in
to reduce the influence of racial/ethnic discrimination on Cancer Prevention and Control is to provide protected time
health care delivery systems in the United States (U.S.). to senior investigators with exceptional mentoring records
This FOA utilizes the NIH Exploratory/Developmental (R21) and sustained, high levels of research productivity in cancer
grant mechanism. prevention, cancer control, or the behavioral or population
Period of Support Up to 2 years sciences to devote to research and mentoring. This Funding
Opportunity Announcement (FOA) utilizes the NIH Senior
Funds/Direct Costs $275,000 direct costs for entire Scientist Award (K05) mechanism.
period of support, up to $200,000
direct costs allowed in any single year
Program Contact Vickie L. Shavers, PhD
6130 Executive Boulevard, Room 4005
Bethesda, MD 20892-7344
(301) 594-1725
shaversv@mail.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 37 of 45
Period of Support Up to 5 years
Funds/Direct Costs Salary support of 25% of the
institutional full-time staff
appointment base salary. The award
also provides $25,000 per year direct MULTIPLE DATES / OTHER
costs resulting from mentored
activities. DEADLINES
Program Contact Susan N. Perkins, PhD
6116 Executive Boulevard, Suite 700 Foundation and Other Sources
Bethesda, MD 20892
(301) 496-8580 Solving Kids' Cancer
perkinsu@mail.nih.gov Clinical Project Grant Awards
Deadline: LOIs accepted on an ongoing basis
Request for Applications (RFA) "http://solvingkidscancer.org/work/grants"
About
Multiple Institutes, including the National Cancer The spirit of a Clinical Idea of Intent request is to inspire the
Institute scientific research community to submit their best ideas for
U.S. – India Bilateral Collaborative Research therapeutic development to improve survivorship for
Partnerships (CRP) on the Prevention of HIV/AIDS children with neuroblastoma, pediatric CNS tumors and
and Co-morbidities (R21) sarcomas. The sponsor seeks testable questions and ideas
about therapies for these childhood cancers that may
RFA-AI-12-033 provide therapeutic solutions where currently there are
Letter of Intent Due Date: August 4, 2012 none. The sponsor's goal is to fund “dream” ideas that are
Application Due Date: September 4, 2012 not currently being funded through existing sources.
"http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12- Period of Support Up to 2 years
033.html" Funds/Direct Costs $25,000 to $300,000 direct costs
About over entire period of support,
This Funding Opportunity Announcement (FOA) solicits depending on the nature of the
Exploratory/Developmental (R21) applications from United proposed project
States (U.S.)-funded institutions with an Indian-institution Budgetary Notes No indirect costs are allowed
partner to establish Collaborative Research Partnerships Program Contact Solving Kids' Cancer
(CRP) in the field of HIV/AIDS prevention or in preventing, 598 Madison Avenue, 6th floor
treating, or ameliorating HIV-related co-morbidities such as
New York, NY 10022
malignancies, metabolic complications or opportunistic
infections (OIs). The U.S.-India Bilateral CRP Program is grants@solvingkidscancer.org
designed to develop collaborations between scientists and
institutions in the U.S. and India to conduct high quality Allos Therapeutics
HIV/AIDS prevention research of mutual interest and benefit Medical Education Grants
to both countries while developing the basis for future
Deadline: Applications accepted on an ongoing basis
institutional and individual scientific collaborations. This
FOA will utilize the research capacities of the institutions "https://grants.allos.com/home/"
and scientists in both countries to advance the field of About
HIV/AIDS prevention and to develop preliminary data that The sponsor is dedicated to the development and
may support a more extensive future research proposal to commercialization of anti-cancer therapeutics. In addition,
test an HIV/AIDS prevention program. This FOA utilizes the the sponsor is currently accepting grants for lymphoma.
NIH (R21) Exploratory/Developmental Research Grant Proposals are reviewed for alignment with the sponsor's
Award mechanism. therapeutic area of interest and educational merit. Please
Period of Support Up to 2 years allow a minimum of six weeks for full review of a request.
Funds/Direct Costs $275,000 direct costs over entire Period of Support Not specified
period of support, up to $200,000 Funds/Direct Costs Not specified
may be requested in any single year
Program Contact Allos Medical Affairs
Program Contact Geraldina Dominguez, PhD
11080 CirclePoint Road, Suite 200
31 Center Drive, Room 3A33
Westminster, CO 80020
Bethesda, MD 20852-2440
(877) 633-3390
(301) 496-3204
grants@allos.com
domingug@mail.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 38 of 45
Elsa U. Pardee Foundation Fanconi Anemia Research Fund, Inc.
Research Grants Head and Neck Carcinogenesis Grant
Deadline: Applications accepted on an ongoing basis Deadline: Applications accepted on an ongoing basis
"http://pardeefoundation.org/grants.aspx" "http://www.fanconi.org/index.php/research/grant_application
About s"
The Elsa U Pardee Foundation funds research directed About
toward identifying new treatments or cures for cancer. The This funding opportunity supports work focused on the
sponsor particularly encourages grant applications for a one molecular pathogenesis, diagnosis, and treatment of head
year period which will allow establishment of capabilities of and neck squamous cell carcinoma in patients with Fanconi
new cancer researchers, or new cancer approaches by anemia (FA). The sponsor will consider the following in
established cancer researchers. Project relevance to making funding decisions: responsiveness of the application
cancer detection, treatment, or cure should be clearly to the problem of head and neck cancer in Fanconi anemia
identified. patients; scientific merit of the proposed project as
Up to 1 year determined by peer review: the degree to which the results
Period of Support
might advance the field, the degree to which the results
Funds/Direct Costs $75,000 to $100,00 per year might improve disease control, the degree to which the
Budgetary Notes Applications requesting more than results might improve the health and well-being of FA
twenty-five percent overhead are patients; and availability of funds.
usually not considered
Period of Support Not specified
Program Contact Lucille M. Dougherty
Funds/Direct Costs Not specified
P.O. Box 2767
Program Contact Fanconi Anemia Research Fund, Inc.
Midland, MI 48641-2767
1801 Willamette Street, Suite 200
(989) 832-3691
Eugene, OR 97401
dougherty@pardeefoundation.org
(541) 687-4658
info@fanconi.org
Pediatric Low Grade Astrocytoma (PLGA)
Foundation
General Motors Foundation
Research Grants
Research Grants
Deadline: LOIs accepted on an ongoing basis
Deadline: Applications accepted on an ongoing basis
"http://www.fightplga.org/research/Apply_for_a_Grant"
"http://www.gm.com/company/aboutGM/gm_foundation.html
About "
The number one priority of the Pediatric Low Grade
About
Astrocytoma (PLGA) Foundation is to act as a catalyst for
researchers world-wide to turn their attention to the area of The General Motors Foundation (GMF) supports
PLGA brain tumors and to award research grants for the organizations working to further research related to the
most promising programs and studies which will lead to a causes, prevention, and treatment of various diseases such
better understanding of the causes of PLGA as well as the as cancer, heart disease, and diabetes. Primary
creation of more effective treatments and a cure for consideration is given to requests that meet the following
pediatric low grade (grades 1 and 2) astrocytoma tumors. criteria:
Proposals related to basic and translational projects that • Exhibit a clear purpose and defined need in one of GMF's
can advance understanding of the underlying biology of the areas of support
development and treatment of PLGA tumors will be • Recognize innovative approaches in addressing the
considered. Investigators in the early years of their careers defined need
are encouraged to apply. • Demonstrate an efficient organization and detail the
organization’s ability to follow through on their proposal
Period of Support Up to 3 years
Period of Support Up to 1 year
Funds/Direct Costs Not specified
Funds/Direct Costs Not specified
Program Contact Pediatric Low Grade Astrocytoma
Foundation (PLGA) Budgetary Notes Indirect costs are not allowed
98 Random Farms Drive Program Contact General Motors Foundation
Chappaqua, NY 10514 cgsupport@cybergrants.com
(914) 762-3494
contact@fightplga.org Shriver (Liddy) Sarcoma Initiative
Research Grants Program
Deadline: Applications accepted on an ongoing basis
"http://sarcomahelp.org/research_center/sarcoma_research
_grants.html"
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 39 of 45
About Period of Support Not specified
The sponsor funds basic research seed grants in sarcoma. Funds/Direct Costs Not specified
The sponsor is interested in a wide range of research. Program Contact Human Genome Sciences
Some examples are: understanding the molecular biology of
14200 Shady Grove Road
sarcomas; exploring "molecular targets" for new sarcoma
therapies; studying chromosomal translocations, the Rockville, MD 20850
oncogenes they generate and their role in sarcoma (877) 822-8472
development; translational studies; studying vaccines, researchgrants@hgsi.com
monoclonal antibodies, and mTOR inhibitors; studying the
use of nanotechnology in the diagnosis and treatment of National Brain Tumor Society
sarcomas; understanding the basis of radiation-induced
sarcoma; modeling of the process of metastases; exploring Innovation Research Grant Program
the differences in the development of sarcomas in children, Deadline: LOIs accepted on an ongoing basis
adolescents, young adults and adults; and research directed "http://www.braintumor.org/research/funding-opportunities/"
at the early detection and diagnosis of sarcoma. Grants can
be used for the development of models, conducting About
experiments, development of sarcoma tissue registries, and The Innovation Research Grant Program is designed to
similar activities involved in support of research into the support catalytic research projects that will significantly
causes, origins, development, molecular biology, diagnosis, move the field forward. These may include "out-of-the-box"
and treatment of sarcoma. The sponsor does not fund projects or research that is critical to move therapies down
clinical trials. the pipeline. Research that represents an incremental
advance is not considered innovative. The National Brain
Period of Support Up to 2 years Tumor Society (NBTS) will accept Letters of Intent (LOI) on
Funds/Direct Costs Funding limit is $25,000 or $50,000 transformative research projects throughout the year.
per year Innovation Grants are designed to invest in promising
Budgetary Notes Grants are not intended to support investigations that may have less existing data or other
the salary of the investigator. Indirect background material than required for Standard and
costs are not allowed. Advanced grants. Researchers in academic or industry labs
Program Contact Shriver (Liddy) Sarcoma Initiative and at all stages of their career may be funded through this
program. NBTS will review Innovation Grant LOIs on a
17 Bethea Drive
quarterly basis. Review Dates: March 18, June 17,
Ossining, NY 10562-1620 September 16, December 16. LOIs submitted within 5
(914) 762-3251 working days of review date will be applied to the next round
info@sarcomahelp.org of reviews. Successful LOI applicants will be invited to
submit a full research grant application.
Human Genome Sciences Period of Support Up to 2 years
Investigator-Sponsored Research Funds/Direct Costs $150,000 direct costs per year
Deadline: Applications accepted on an ongoing basis Budgetary Notes Indirect costs are not allowed
"http://www.hgs-isr.com/" Program Contact Carrie Treadwell
About 124 Watertown Street, Suite 2D
The sponsor's Investigator-Sponsored Research (ISR) Watertown, MA 02472-2500
program provides support for research, initiated and (617) 924-9997
sponsored by researchers, that advances medical ctreadwell@braintumor.org
knowledge, enhances scientific understanding of disease or
may lead to novel interventions. The following types of Accelerate Brain Cancer Cure
research are eligible for support: 1) clinical studies of uses
of Human Genome Sciences (HGS) products for Research Grants
autoimmune diseases, cancer, and hepatitis. 2) Deadline: Proposals accepted on an ongoing basis
observational studies such as epidemiology studies and "http://www.abc2.org/smarter-research/how-we-fund"
outcomes research studies with a primary focus being to
enhance scientific understanding of autoimmune disease, About
cancer, and hepatitis. 3) in vitro or in vivo studies with The research funding process for Accelerate Brain Cancer
requests for funding or product. Funding requests must be Cure (ABC2) is designed to move the best ideas into the
submitted at least 6 weeks prior to the start date of the clinic as soon as possible. The sponsor believes that
program, to ensure there is adequate time for requests to innovation and solid research should not linger in research
be reviewed and processed. Applying for research support labs. Proposals need to identify a clear problem and lay out
is a two-step process: 1) submission of an initial Concept a clear roadmap to find a solution. Since speed counts,
Proposal that, if of interest to HGS, is followed by 2) rather than simply issuing a yearly request for proposals
submission of a detailed Protocol with budget. A request for (RFP), the sponsor constantly scouts research labs for
submission of a protocol should not be considered a advances which can be translated into new treatments for
commitment to provide funds. patients. ABC2 funds projects at each stage of the
therapeutic development pipeline to ensure promising leads
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 40 of 45
are advanced as quickly as possible. marrow failure, myelodysplasia and leukemia in Fanconi
anemia, and to develop strategies to prevent, treat and cure
Period of Support Not specified
these disorders; to define the molecular pathogenesis of
Funds/Direct Costs Not specified clonal evolution and carcinogenesis in Fanconi anemia, and
Program Contact David Sandak to develop strategies to prevent, treat and cure Fanconi
1717 Rhode Island Avenue, NW, anemia-associated malignancies; and to support the
Suite 700 creation of shared resources and technologies for the
Washington, DC 20036 international Fanconi anemia research community.
(202) 419-3140 Period of Support Up to 2 years
david.sandak@abc2.org Funds/Direct Costs Not specified
Program Contact Beverly Mayhew, Executive Director
Gateway for Cancer Research 1801 Willamette Street, Suite 200
Research Grant Eugene, OR 97401
Deadline: LOIs are accepted on an ongoing basis (541) 687-4658
"http://www.demandcurestoday.org/cancer-research/grant- bev@fanconi.org
application"
About The Milken Family Foundation
Gateway’s research mission is supporting patient-centered Grants Program
research that improves treatment outcomes and restores Deadline: Applications accepted on an ongoing basis
patients’ quality of life. Gateway funds 1-year and 2-year "http://www.mff.org/about/about.taf?page=funding"
human clinical studies that are treatment-based and
focused on true clinical innovation or novel About
concepts/approaches. True clinical innovation is defined as The Milken Family Foundation’s (MFF) purpose is to
a therapeutic approach that potentially changes the course discover inventive ways of helping people help themselves
of future therapy. Novel concept/approach is defined as a and those around them to lead productive and satisfying
new combination use or the use of a compound for a lives. Developing human potential through education and
different disease. Believing that patients’ option are fighting protecting human well-being through the channels of
cancer though an integrated oncology model, Gateway medicine are the chief means by which the Foundation
supports innovative clinical research in conventional as well pursues this aim. The MFF is committed to advancing and
as complementary therapies. supporting basic and applied medical research -- especially
in the areas of prostate cancer and epilepsy -- and
Period of Support Up to 2 years
recognizing and rewarding outstanding scientists in these
Funds/Direct Costs Not specified. Applicants should areas; and supporting basic health care programs to assure
apply for the amount they believe is the well-being of community members of all ages.
needed to conduct their clinical trial.
Budgetary Notes Seed money will be awarded at the Period of Support Not specified
beginning of the trial for startup Funds/Direct Costs Not specified
costs. After that patient impact must Program Contact Richard Sandler, Executive VP
be demonstrated through monthly 1250 Fourth Street
update forms in order to trigger the Santa Monica, CA 90401-1353
next payment.
(310) 570-4800
Program Contact Eveline Mumenthaler
admin@mff.org
1336 Basswood Road
Schaumburg, IL 60173
Robert Wood Johnson Foundation
(847) 342-7450
Proposals for Unsolicited Grants
eveline.mumenthaler@gatewaycr.org
Deadline: Applications accepted on an ongoing basis
Fanconi Anemia Research Fund, Inc. "http://www.rwjf.org/applications/unsolicited/unsolicitedgrants
.jsp"
Research Grants Program
About
Deadline: Applications accepted on an ongoing basis
Robert Wood Johnson Foundation (RWJF) accepts
"http://www.fanconi.org/index.php/research/grant_application
unsolicited proposals at any time in the Pioneer Portfolio.
s"
The most promising unsolicited proposals will: 1) address
About the strategic objectives of the Pioneer Portfolio 2) be new
The sponsor's research priorities are: to identify the Fanconi and/or innovative 3) be best suited for funding through
anemia (FA) genes and their products and to understand RWJF—rather than through local, public or private sources
their functions, interactions and roles in producing the of funding 4) be sustainable without relying on ongoing
clinical manifestations of FA; to advance basic and clinical RWJF funding 5) show potential for measurable impact and
research studies to improve FA diagnosis, therapy, and meaningful change.
disease prevention; to determine the causes of bone
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 41 of 45
Period of Support Not specified UM/Scientific Awards Committee
Funds/Direct Costs Not specified
Pilot Study Grants
Program Contact Robert Wood Johnson Foundation
Deadline: Applications accepted on an ongoing basis
P.O. Box 2316
"http://uresearch.miami.edu/?fo_order=publishdate&fo_ordir
Princeton, NJ 08543 =asc&fo_page=1&fo_search=1&item=20&p=43&pid=160&m
(877) 843-7953 =fundingph&mid=2&fo_desc=&fo_spr=&fo_pl=&fo_dl=&fo_is
mail@rwjf.org ls=A*"
About
International Waldenstrom's Macroglobulinemia Pilot Study Grants provide support to assist faculty in jump-
Foundation starting new research areas, including new and distinct
Research Grant Program research areas where the applicant has no existing funding
or publications, as well as new direction(s) for existing
Deadline: Applications accepted on an ongoing basis
research programs in which the applicant has past
"http://www.iwmf.com/research/applying-for-a-grant.aspx" experience but no current funding. All full time faculty at the
About Miller School of Medicine are eligible. Preference will be
The International Waldenstrom's Macroglobulinemia given to faculty who have been granted their appointments
Foundation (IWMF) Research Grant Program is pledged to at least three years before the SAC meeting at which their
promote and support research leading to improved applications are to be considered. Applications are due on
understanding of the cause, diagnosis, treatment, and cure the 18th of each month (July – March).
for the disease Waldenstrom’s macroglobulinemia. Period of Support Up to 1 year
Period of Support Up to 2 years Funds/Direct Costs Up to $20,000 in direct research
Funds/Direct Costs Up to $100,000 over entire period of costs
support Program Contact Karen Del Rio
Budgetary Notes Up to 8% indirect costs are allowed 1120 NW 14th Street, CRB 650H
Program Contact Tom Myers Miami, FL 33136
23 State Park Road (305) 243-5370
Swanton, MD 21561 kdelrio@.miami.edu
(301) 616-9200
tom@mountaineerlog.com UM/Scientific Awards Committee
Bridge Funding Grants
Intramural Funding Opportunities Deadline: Applications accepted on an ongoing basis
"http://uresearch.miami.edu/?p=43&pid=160&m=fundingph&
University of Miami Miller School of Medicine mid=2&item=21"
Dean's NIH Bridge Program About
Deadline: Applications accepted on an ongoing basis Bridge Funding Grants provide support to assist faculty in
"http://uresearch.miami.edu/?p=169&s=33#med" maintaining their research program in the event of a funding
lapse during the process of applying for additional
About extramural funding. Applications are due on the 18th of
University of Miami Miller School faculty will likely need each month (July – March).
additional application cycles in order to successfully obtain
Period of Support Up to 1 year
new NIH awards and competitive renewals. These gaps in
funding may put research programs at risk, many of which Funds/Direct Costs Up to $25,000 in direct research
have taken significant resources and years to build. In order costs
to maintain the continuity of our outstanding research Budgetary Notes Support for faculty salary will not be
programs, a pool of resources is available to sustain provided but the percent effort that
research that is competitive for NIH funding. These funds the PI and other personnel will spend
are available for up to one year while new or renewed on the project should be stated in the
support is pursued. budget and will be considered as
matching funds.
Period of Support Up to 1 year
Program Contact Karen Del Rio
Funds/Direct Costs Up to 50% of the recommended 1st
year Direct Cost budget (excluding Room C604 Clin Research Bldg
faculty salaries) 1120 NW 14th Street
Program Contact Karen Del Rio Miami, FL 33136
1120 NW 14th Street, CRB 650H (305) 243-5370
Miami, FL 33136 kdelrio@.miami.edu
(305) 243-5370
kdelrio@med.miami.edu
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 42 of 45
NEW NEW
UM/Scientific Awards Committee Multiple Institutes, including the National Cancer
Post-A1 Re-Tooling Grants Institute
Deadline: Applications accepted on an ongoing basis Ethical Issues in Research on HIV/AIDS and its Co-
"http://uresearch.miami.edu/default.asp?p=265" morbidities (R01)
About PAR-12-244
The Post-A1 Re-Tooling Grants assist faculty who are no Deadline: Multiple Dates - Please see Announcement
longer eligible for Bridge funding, but will support them when 'http://grants.nih.gov/grants/guide/pa-files/PAR-12-244.html"
their NIH Research Grant (R-series) A1 (revised) application
About
is not funded. This transition phase will allow faculty to "re-
tool" their specific aims and research plan for a new NIH This Funding Opportunity Announcement (FOA) invites
submission. Applications are due on the 18th of each month applications addressing ethical issues in research relevant
(July – March). to populations with HIV and associated co-morbidities, and
populations at high risk of HIV acquisition. The bioethics
Period of Support Up to 1 year projects supported through this program announcement will
Funds/Direct Costs Up to $25,000 in direct research focus on at least one of the following three goals: 1)
costs development of the empirical knowledge base for human
Program Contact Karen Del Rio subjects protection and ethics standards in HIV/AIDS
1120 NW 14th Street, CRB 650H research; 2) development of conceptual bioethics
approaches to advance scholarship on difficult ethical
Miami, FL 33136 challenges in HIV/AIDS research; 3) supporting the
(305) 243-5370 integration of bioethics work with ongoing research in
kdelrio@miami.edu HIV/AIDS. This FOA utilizes the NIH (R01) Research
Project Grant mechanism.
UM/Scientific Awards Committee Period of Support Up to 5 years
Emergency Equipment Grants Funds/Direct Costs Application budgets are not limited,
Deadline: Applications accepted on an ongoing basis but need to reflect actual needs of
"http://uresearch.miami.edu/?fo_order=publishdate&fo_ordir the proposed project
=asc&fo_page=1&fo_search=1&item=22&p=43&pid=160&m Program Contact Rebecca Liddell Huppi, PhD
=fundingph&mid=2&fo_desc=&fo_spr=&fo_pl=&fo_dl=&fo_is 31 Center Drive, Room 3A33
ls=A*" Bethesda, MD 20892-2440
About (301) 496-4995
Emergency Equipment Grants provide support to replace or liddellr@exchange.nih.gov
repair intensively used equipment that unexpectedly breaks
down or to upgrade existing equipment. These grants are Multiple Institutes, including the National Cancer
not intended to cover routine or anticipated repair, Institute
maintenance, or service contracts. All full time faculty at the
Miller School of Medicine are eligible. Applications are due Administrative Supplements to Existing NIH
on the 18th of each month (July – March). Grants and Cooperative Agreements (Parent
Period of Support Up to 1 year Admin Supp)
Funds/Direct Costs Up to $20,000 in direct research PA-12-100
costs Deadline: Due dates may vary by awarding IC.
Program Contact Karen Del Rio "http://grants.nih.gov/grants/guide/pa-files/PA-12-100.html"
1120 NW 14th Street, CRB 650H About
Miami, FL 33136 The National Institutes of Health (NIH) hereby notify
(305) 243-5370 Principal Investigators holding specific types of NIH
kdelrio@med.miami.edu research grants, listed in the full Funding Opportunity
Announcement (FOA) that funds may be available for
administrative supplements to meet increased costs that are
Program Announcements (PA) within the scope of the approved award, but that were
unforeseen when the new or renewal application or grant
progress report for non-competing continuation support was
submitted. Applications for administrative supplements are
considered prior approval requests (as described in Section
8.1.2.11 of the NIH Grants Policy Statement) and will be
routed directly to the Grants Management Officer of the
parent award. Although requests for administrative
supplements may be submitted through this FOA, there is
no guarantee that funds are available from the awarding IC
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 43 of 45
(NIH Institute or Center) or for any specific grant. All NEW
applicants are encouraged to discuss potential requests National Cancer Institute
with the awarding IC. Additionally, prior to submission,
applicants must review the awarding IC's web site to ensure Physical Activity and Weight Control Interventions
they meet the IC's requirements. A list of those web sites is Among Cancer Survivors: Effects on Biomarkers
available at of Prognosis and Survival (R21)
http://grants.nih.gov/grants/guide/admin_supp/index.htm. PAR-12-229
Period of Support Within currently approved project Deadline: Multiple Dates - Please see Announcement
period "http://grants.nih.gov/grants/guide/pa-files/PAR-12-229.html"
Funds/Direct Costs Application budgets are generally About
limited to no more than the amount
of the most recent parent award, and This Funding Opportunity Announcement (FOA)
must reflect actual needs of the encourages transdisciplinary and translational research that
proposed project. will identify specific biological or biobehavioral pathways
through which physical activity and/or weight control (either
Program Contact Program Officer listed on parent award weight loss or avoidance of weight gain) may affect cancer
prognosis and survival. Research applications must test the
NEW effects of physical activity or weight control or both
National Cancer Institute interventions on biomarkers of cancer prognosis among
cancer survivors identified by previous animal or
Physical Activity and Weight Control Interventions
observational research, which may include but are not
Among Cancer Survivors: Effects on Biomarkers limited to intervention-induced changes in sex hormones,
of Prognosis and Survival (R01) insulin or insulin-like growth factors or their binding proteins,
PAR-12-228 insulin resistance, glucose metabolism, leptin and other
Deadline: Multiple Dates - Please see Announcement adipokines, immunologic or inflammatory factors, oxidative
stress and DNA damage or repair capacity, angiogenesis,
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-228.html'
or prostaglandins. This research will require
About transdisciplinary approaches that bring together behavioral
This Funding Opportunity Announcement (FOA) intervention expertise, cancer biology, and other basic and
encourages transdisciplinary and translational research that clinical science disciplines relevant to the pathways being
will identify specific biological or biobehavioral pathways studied. This FOA utilizes the NIH (R21)
through which physical activity and/or weight control (either Exploratory/Developmental Research Grant Award
weight loss or avoidance of weight gain) may affect cancer mechanism.
prognosis and survival. Research applications must test the Period of Support Up to 2 years
effects of physical activity or weight control or both
Budgetary Notes $275,000 direct costs over entire
interventions on biomarkers of cancer prognosis among
period of support, with no more than
cancer survivors identified by previous animal or
$200,000 requested in any single
observational research, which may include but are not
year
limited to intervention-induced changes in sex hormones,
insulin or insulin-like growth factors or their binding proteins, Program Contact Catherine M. Alfano, PhD
insulin resistance, glucose metabolism, leptin and other 6116 Executive Boulevard, Suite 404
adipokines, immunologic or inflammatory factors, oxidative Bethesda, MD 20892-8336
stress and DNA damage or repair capacity, angiogenesis, (301) 402-1450
or prostaglandins. This research will require alfanoc@mail.nih.gov
transdisciplinary approaches that bring together behavioral
intervention expertise, cancer biology, and other basic and
clinical science disciplines relevant to the pathways being NEW
studied. This FOA utilizes the NIH (R01) Research Project Multiple Institutes, including the National Cancer
Grant mechanism. Institute
Period of Support Up to 5 years Ethical Issues in Research on HIV/AIDS and its Co-
Funds/Direct Costs Application budgets are not limited, morbidities (R21)
but need to reflect actual needs of PAR-12-243
the proposed project.
Deadline: Multiple Dates - Please see Announcement
Program Contact Catherine M. Alfano, PhD
"http://grants.nih.gov/grants/guide/pa-files/PAR-12-243.html"
6116 Executive Boulevard, Suite 404
Bethesda, MD 20892-8336 About
(301) 402-1450 This Funding Opportunity Announcement (FOA) invites
applications addressing ethical issues in research relevant
alfanoc@mail.nih.gov to populations with HIV and associated co-morbidities, and
populations at high risk of HIV acquisition. The bioethics
projects supported through this program announcement will
focus on at least one of the following three goals: 1)
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 44 of 45
development of the empirical knowledge base for human
subjects protection and ethics standards in HIV/AIDS
research; 2) development of conceptual bioethics
approaches to advance scholarship on difficult ethical
challenges in HIV/AIDS research; 3) supporting the
integration of bioethics work with ongoing research in
HIV/AIDS. This FOA utilizes the NIH (R21)
Exploratory/Developmental Research Grant Award
mechanism.
Period of Support Up to 2 years
Funds/Direct Costs $275,000 direct costs over entire
period of support, with no more than
$200,000 requested in any single
year
Program Contact Rebecca Liddell Huppi, PhD
31 Center Drive, Room 3A33
Bethesda, MD
(301) 496-4995
liddellr@exchange.nih.gov
SCCC Research Administration AUGUST 2012 Funding Newsletter Page 45 of 45
